Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:sssptaul25rxt
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Dec 17 The CA Lexicon available in the CAPLUS and CA files
NEWS 3 Feb 06 Engineering Information Encompass files have new names
NEWS 4 Feb 16 TOXLINE no longer being updated
NEWS 5 Apr 23 Search Derwent WPINDEX by chemical structure
NEWS 6 Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS 7 May 07 DGENE Reload

NEWS EXPRESS April 18 CURRENT WINDOWS VERSION IS V6.0,
CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP),
AND CURRENT DISCOVER FILE IS DATED 04/06
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:29:52 ON 14 MAY 2001

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'REGISTRY' ENTERED AT 13:29:59 ON 14 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 13 MAY 2001 HIGHEST RN 335276-85-2

DICTIONARY FILE UPDATES: 13 MAY 2001 HIGHEST RN 335276-85-2

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT for details.

=> e clomiphene

```
E1            1     CLOMINOREX/BI
E2            9     CLOMIPHEN/BI
E3            9 --> CLOMIPHENE/BI
E4           15     CLOMIPR/BI
E5           15     CLOMIPRAMINE/BI
E6            1     CLOMIVID/BI
E7            1     CLOMOCYCLINE/BI
E8            2     CLOMOXIR/BI
E9            1     CLOMPHID/BI
E10           3     CLOMU10COM/BI
E11        1808     CLON/BI
E12           1     CLONA/BI
```

=> s e3

```
L1            9 CLOMIPHENE/BI
```

=> e thianaphthene

```
E1           14     THIANAPHTHE/BI
E2           23     THIANAPHTHEN/BI
E3          132 --> THIANAPHTHENE/BI
E4            1     THIANAPHTHENEACETIC/BI
E5            1     THIANAPHTHENEACETYL/BI
E6            2     THIANAPHTHENECARBOX/BI
E7            2     THIANAPHTHENECARBOXALDEHYDE/BI
E8            1     THIANAPHTHENEPROPIONIC/BI
E9            1     THIANAPHTHENEQUIN/BI
E10           1     THIANAPHTHENEQUINONE/BI
E11          59     THIANAPHTHENO/BI
E12          14     THIANAPHTHENON/BI
```

=> s e3

```
L2          132 THIANAPHTHENE/BI
```

=> file ca

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	8.22	8.37

FILE 'CA' ENTERED AT 13:31:10 ON 14 MAY 2001

26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 10 May 2001 VOL 134 ISS 21
FILE LAST UPDATED: 10 May 2001 (20010510/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

The CA file now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

Attention, the CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
=> s l1

L3        1272 L1

=> s l2

L4        3002 L2

=> e contraceptive

E1           1     CONTRACEPTIONS/BI
E2           1     CONTRACEPTIV/BI
E3        9654 --> CONTRACEPTIVE/BI
E4           9     CONTRACEPTIVELY/BI
E5       11230     CONTRACEPTIVES/BI
E6           1     CONTRACEPTIVITY/BI
E7           1     CONTRACEPVIES/BI
E8           1     CONTRACER/BI
E9           1     CONTRACETILE/BI
E10          8     CONTRACETIVE/BI
E11          2     CONTRACETIVES/BI
E12          2     CONTRACETPIVES/BI

=> s e3-e5

          9654 CONTRACEPTIVE/BI
             9 CONTRACEPTIVELY/BI
         11230 CONTRACEPTIVES/BI
L5       12649 (CONTRACEPTIVE/BI OR CONTRACEPTIVELY/BI OR CONTRACEPTIVES/BI)

=> s l3 and l5

L6          34 L3 AND L5

=> d l6 1-34
```

L6 ANSWER 1 OF 34 CA COPYRIGHT 2001 ACS
AN 133:261948 CA
TI Method for a programmed controlled ovarian stimulation protocol
IN Engel, Jurgen; Riethmuller-winzen, Hilde
PA Asta Medica A.-G., Germany
SO PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000059542	A1	20001012	WO 2000-EP2466	20000321

W: AU, BG, BR, BY, CA, CN, CZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, UZ, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRAI US 1999-127241 P 19990331
US 1999-131632 P 19990428
RE.CNT 6
RE
(1) Albano, C; HUMAN REPRODUCTION 1996, V11/10(2114-2118)
(2) Asta Medica Ag; EP 0788799 A 1997 CA
(3) Asta Medica Ag; CA 2200541 A 1998 CA
(4) Bouchard, P; OVULATION INDUCTION: UPDATE: THE PROCEEDINGS OF THE WORLDCONGRESS ON OVULATION INDUCTION 1998, P115 CA
(5) Felberbaum, R; IN VITRO FERT ASSISTED REPROD, PROC WORLD CONGR 1997, P397 CA
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 34 CA COPYRIGHT 2001 ACS
AN 123:276262 CA
TI Estrogenic and antiestrogenic activities of anordiol: A comparison of uterine and vaginal responses with those of clomiphene citrate
AU Peters, Albert J.; Wentz, Anne Colston; Kazer, Ralph R.; Jeyendran, Rajasingam S.; Chatterton, Robert T. Jr.
CS Division Obstetrics/Gynecology, Geisinger Medical Center, Danville, PA, 17822, USA
SO Contraception (1995), 52(3), 195-202
CODEN: CCPTAY; ISSN: 0010-7824
DT Journal
LA English

L6 ANSWER 3 OF 34 CA COPYRIGHT 2001 ACS
AN 123:189355 CA
TI Ovulation control by regulating nitric oxide levels
IN Garfield, Robert E.; Yallampalli, Chandrasekhar
PA Board of Regents, University of Texas System, USA
SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9515753	A1	19950615	WO 1994-US14133	19941208

W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

	US 5470847	A	19951128	US 1993-165309	19931210
	AU 9513041	A1	19950627	AU 1995-13041	19941208
	US 5643944	A	19970701	US 1995-477189	19950607
	US 5721278	A	19980224	US 1995-477187	19950607
PRAI	US 1993-165309		19931210		
	WO 1994-US14133		19941208		

L6 ANSWER 4 OF 34 CA COPYRIGHT 2001 ACS
AN 121:196203 CA
TI Effect of anordiol on ovarian hormone secretion, ovulation, and uterine and vaginal responses in the immature rat
AU Lu, Y -C.; Chatterton, R. T. Jr
CS Department Obstetrics and Gynecology, Northwestern University Medical School, Chicago, IL, 60611, USA
SO Adv. Contracept. (1994), 10(2), 157-66
CODEN: ADCOEB; ISSN: 0267-4874
DT Journal
LA English

L6 ANSWER 5 OF 34 CA COPYRIGHT 2001 ACS
AN 116:207993 CA
TI Inhibition of decidual induction in rats by clomiphene and tamoxifen
AU Barkai, Uriel; Kidron, Tamar; Kraicer, P. F.
CS George S. Wise Fac. Life Sci., Tel Aviv Univ., Ramat Aviv, 69978, Israel
SO Biol. Reprod. (1992), 46(4), 733-9
CODEN: BIREBV; ISSN: 0006-3363
DT Journal
LA English

L6 ANSWER 6 OF 34 CA COPYRIGHT 2001 ACS
AN 111:187732 CA
TI Induction and promotion of .gamma.-glutamyltranspeptidase-positive foci in
the liver of female rats treated with ethinylestradiol, clomiphene, tamoxifen and their associations
AU Ghia, M.; Mereto, E.
CS Inst. Pharmacol., Univ. Genoa, Genoa, I-16132, Italy
SO Cancer Lett. (Shannon, Irel.) (1989), 46(3), 195-202
CODEN: CALEDQ; ISSN: 0304-3835
DT Journal
LA English

L6 ANSWER 7 OF 34 CA COPYRIGHT 2001 ACS
AN 111:17857 CA
TI Experimental antifertility effect of clomiphene citrate
AU Yan, Jingming; Zhou, Kangmei; Wang, Jing; Cai, Zhengquan
CS Inst. Obstet. Gynecol., Shanghai Med. Univ., Shanghai, Peop. Rep. China
SO Shanghai Yike Daxue Xuebao (1989), 16(1), 55-7
CODEN: SYDXEE; ISSN: 0257-8131
DT Journal
LA Chinese

L6 ANSWER 8 OF 34 CA COPYRIGHT 2001 ACS
AN 109:148321 CA
TI Vitamin B6 treatment of premenstrual syndrome
AU Brush, M. G.
CS Dep. Gynaecol., United Med. Dent. Sch., London, SE1 7EH, UK
SO Curr. Top. Nutr. Dis. (1988), 19(Clin. Physiol. Appl. Vitam. B-6), 363-79
CODEN: CTNDDU; ISSN: 0191-2453
DT Journal
LA English

L6 ANSWER 9 OF 34 CA COPYRIGHT 2001 ACS

AN 108:16889 CA
TI **Contraceptive** compositions comprising a progesterone antagonist and a blocker of progesterone activity
PA Yeda Research and Development Co. Ltd., Israel
SO Israeli, 6 pp.
CODEN: ISXXAQ
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	IL 68222	A1	19870227	IL 1983-68222	19830324
	US 4670426	A	19870602	US 1984-672716	19841119
PRAI	IL 1983-68222		19830324		
	US 1984-581023		19840216		

L6 ANSWER 10 OF 34 CA COPYRIGHT 2001 ACS
AN 100:168449 CA
TI The effect of sex steroids and hormonal **contraceptives** upon thymus and spleen of intact female rats
AU Kuhl, H.; Gross, M.; Schneider, M.; Weber, W.; Mehlis, W.; Stegmueller, M.; Taubert, H. D.
CS Abt. Gynaekol. Endokrinol., J. W. Goethe-Univ., Frankfurt/Main, D-6000, Fed. Rep. Ger.
SO Contraception (1983), 28(6), 587-601
CODEN: CCPTAY; ISSN: 0010-7824
DT Journal
LA English

L6 ANSWER 11 OF 34 CA COPYRIGHT 2001 ACS
AN 92:104884 CA
TI Effects of several estrogenic compounds on corticosteroid binding globulin (CBG) in the human, and estrogen thresholds for increasing serum CBG
AU Kawagoe, S.; Hiroi, M.; Moore, D. E.; Nakamura, R. M.
CS Yamagata Univ., Yamagata, Japan
SO Proc. - Asian Congr. Obstet. Gynaecol., 7th (1977), 819-21. Editor(s): Toongsuwan, Sommai; Suvonnakote, Thaviponk. Publisher: Publication Sub-Comm. Seventh Asian Congr. Obstet. Gynaecol., Bangkok, Thailand.
CODEN: 42IEAI
DT Conference
LA English

L6 ANSWER 12 OF 34 CA COPYRIGHT 2001 ACS
AN 89:174259 CA
TI Concentrations of prostaglandins F2.alpha. and E2 in the endometrium throughout the human menstrual cycle, after the administration of clomiphene or an estrogen-progestagen pill and in early pregnancy
AU Maathuis, J. B.; Kelly, R. W.
CS Unit Reprod. Biol., MRC, Edinburgh, Scot.
SO J. Endocrinol. (1978), 77(3), 361-71
CODEN: JOENAK; ISSN: 0022-0795
DT Journal
LA English

L6 ANSWER 13 OF 34 CA COPYRIGHT 2001 ACS
AN 88:69587 CA
TI Post-pill amenorrhea: investigation and therapeutic response
AU Israel, R.; March, C. M.; Kletzky, O.
CS Women's Hosp., Los Angeles, Calif., USA
SO Proc. Serono Symp. (1976), 8(Ovul. Hum.), 181-92
CODEN: PSSYDG
DT Journal

LA English

L6 ANSWER 14 OF 34 CA COPYRIGHT 2001 ACS
AN 86:187198 CA
TI Nonpuerperal galactorrhea and hyperprolactinemia. Clinical findings, endocrine features and therapeutic responses in 56 cases
AU Gomez, Fulgencio; Reyes, Francisco I.; Faiman, Charles
CS Dep. Physiol., Univ. Manitoba, Winnipeg, Manitoba, Can.
SO Am. J. Med. (1977), 62(5), 648-60
CODEN: AJMEAZ
DT Journal
LA English

L6 ANSWER 15 OF 34 CA COPYRIGHT 2001 ACS
AN 86:37944 CA
TI GPC diesterase activity in human endometrial secretion. (Its variations under the action of estrogens, clomiphene citrate, D-norgestrel (post-coital and low dose) and intrauterine device (IUD))
AU Nicholson, Roberto; Calamera, Juan C.
CS Fac. Med., Univ. Buenos Aires, Buenos Aires, Argent.
SO Int. J. Fertil. (1976), 21(3), 177-80
CODEN: INJFA3
DT Journal
LA English

L6 ANSWER 16 OF 34 CA COPYRIGHT 2001 ACS
AN 84:84690 CA
TI Induction of ovulation. Comparative study of the ovarian response to treatment with human gonadotropins, synthetic luteinizing hormone-releasing hormone, and nonhormonal agents (clomiphene, cyclophenyl, etc.). Therapeutic projections in the treatment of anovulatory sterility
AU Zanartu, Juan; Dabancens, Alfredo; Rodriguez-Bravo, Rogelio; Schally, Andrew V.
CS Fac. Med., Univ. Chile, Santiago, Chile
SO Rev. Chil. Obstet. Ginecol. (1973), 38(5), 240-51
CODEN: RCOBA4
DT Journal
LA Spanish

L6 ANSWER 17 OF 34 CA COPYRIGHT 2001 ACS
AN 81:99885 CA
TI Post nidatory action of various compounds representing several pharmacological classes
AU DiPasquale, Gene; Richter, Ralph
CS Dep. Endocrinol., Warner-Lambert Res. Inst., Morris Plains, N. J., USA
SO Res. Commun. Chem. Pathol. Pharmacol. (1974), 7(4), 701-14
CODEN: RCOCB8
DT Journal
LA English

L6 ANSWER 18 OF 34 CA COPYRIGHT 2001 ACS
AN 79:210 CA
TI Antifertility effect of three new clomiphene analogs on animals
AU Basu, Jayasree
CS Reprod. Biol. Div., Indian Inst. Exp. Med., Calcutta, India
SO Jap. J. Exp. Med. (1973), 43(1), 9-15
CODEN: JJEMAG
DT Journal
LA English

L6 ANSWER 19 OF 34 CA COPYRIGHT 2001 ACS
AN 78:47800 CA

TI 2-[p-2-Chloro-1,2-diphenylvinyl)phenoxy]triethylamine **contraceptive**
IN Holtkamp, Dorsey E.
PA Richardson-Merrell Inc.
SO Fr. Demande, 7 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2110234		19720707		
PRAI	US 1970-78259		19701005		

L6 ANSWER 20 OF 34 CA COPYRIGHT 2001 ACS
AN 78:20205 CA
TI Oral **contraceptive** formulations
IN MacGregor, Alexander Hamilton; Holtkamp, Dorsey Emil
PA Richardson-Merrell Inc.
SO Ger. Offen., 19 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2218016	A	19721109	DE 1972-2218016	19720414
	ZA 7201930	A	19721227	ZA 1972-1930	19720321
	FR 2133862	A5	19721201	FR 1972-13627	19720418
	FR 2133862	B1	19750620		
	BE 782321	A1	19720816	BE 1972-116498	19720419
PRAI	US 1971-135430		19710419		

L6 ANSWER 21 OF 34 CA COPYRIGHT 2001 ACS
AN 77:52319 CA
TI Fertility-preventing compositions
IN Holtkamp, Dorsey Emil; Petrow, Vladimir
PA Richardson-Merrell Inc.
SO Ger. Offen., 19 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2149281	A	19720406	DE 1971-2149281	19711002
	ZA 7106118	A	19720531	ZA 1971-6118	19710913
	GB 1326528	A	19730815	GB 1971-43764	19710920
	IL 37772	A1	19750425	IL 1971-37772	19710923
	AU 7134060	A1	19730405	AU 1971-34060	19710930
	CA 963806	A1	19750304	CA 1971-124085	19710930
	BE 773518	A1	19720131	BE 1971-108949	19711005
	FR 2110233	A1	19720602	FR 1971-35858	19711005
	FR 2110233	A5	19720602		
PRAI	US 1970-78258		19701005		

L6 ANSWER 22 OF 34 CA COPYRIGHT 2001 ACS
AN 76:149371 CA
TI Inhibition of capacitation in the rabbit
AU Hamner, Charles E.; Wilson, Lester A., Jr.
CS Med. Sch., Univ. Virginia, Charlottesville, Va., USA
SO Fert. Steril. (1972), 23(3), 196-200
CODEN: FESTAS

DT Journal
LA English

L6 ANSWER 23 OF 34 CA COPYRIGHT 2001 ACS
AN 76:81565 CA
TI Effect of ten **contraceptive** drugs on voluntary alcohol consumption in albino rats
AU Eriksson, Kalervo
CS Res. Lab., State Alcohol Monop. (Alko), Helsinki, Finland
SO Arukoru Kenkyu (1971), 6(1), 9-11
CODEN: JJSAAG
DT Journal
LA English

L6 ANSWER 24 OF 34 CA COPYRIGHT 2001 ACS
AN 75:46300 CA
TI HFSH [human follicle-stimulating hormone] and HLH [human luteinizing hormone] radioimmunological assay during the diurnal cycle, ovulation, and the suppression of the gonadotropic pituitary effect
AU Dolais, J.; Rosselin, G.
CS Groupe Rech. Diabetol. Etud. Radio-Immunol. Horm. Proteiques, Inst. Natl. Sante Rech. Med., Paris, Fr.
SO Int. Congr. Clin. Chem., [Proc.], 7th (1971), Meeting Date 1969, Volume 3, 181-95. Editor(s): Roth, Marc. Publisher: Karger, Basel, Switz.
CODEN: 23ENAA
DT Conference
LA English

L6 ANSWER 25 OF 34 CA COPYRIGHT 2001 ACS
AN 74:94969 CA
TI Effect of ovarian steroids on hepatic metabolism. II. Estrogens
AU Fahim, Mostafa S.; Hall, David Goodsell; Jones, Tom
CS Sch. Med., Univ. Missouri, Columbia, Mo., USA
SO Amer. J. Obstet. Gynecol. (1971), 109(4), 558-63
CODEN: AJOGAH
DT Journal
LA English

L6 ANSWER 26 OF 34 CA COPYRIGHT 2001 ACS
AN 74:85289 CA
TI Gonadotropin secretion in man
AU Franchimont, Paul
CS Med. Inst., Univ. Luettich, Liege, Belg.
SO Muenchen. Med. Wochenschr. (1970), 112(51), 2303-12
CODEN: MMWOAU
DT Journal
LA German

L6 ANSWER 27 OF 34 CA COPYRIGHT 2001 ACS
AN 74:72244 CA
TI Experimental and clinical studies on the effect of clomiphene and gestagens on the gonadotropic function of the adenohypophysis
AU Hohlweg, W.; Mayer, H. G. K.
CS Universitaetsfrauenklin., Graz, Austria
SO Bull. Schweiz. Akad. Med. Wiss. (1970), 25(4-6), 374-8
CODEN: BSAMA5
DT Journal
LA German

L6 ANSWER 28 OF 34 CA COPYRIGHT 2001 ACS
AN 72:51491 CA

TI Effects of clomiphene and gonadotropin on ovarian function in women with steroid-induced iatrogenic anovulation
AU Zanartu, Juan; Pupkin, Marcos; Rosenberg, David; Mendez, Gustavo; Stone, Sergio; Guerrero, Rodolfo; Puga, Juan
CS Hosp. Clin. J. Joaquin Aguirre, Santiago de Chile, Chile
SO Rev. Chil. Obstet. Ginecol. (1968), 33(6), 345-52
CODEN: RCOBA4
DT Journal
LA Spanish

L6 ANSWER 29 OF 34 CA COPYRIGHT 2001 ACS
AN 70:112103 CA
TI Effect of oral **contraceptives** on plasma follicle-stimulating hormone
AU Cargille, C. M.; Ross, Griff T.; Rayford, Phillip L.
CS Nat. Cancer Inst., Nat. Inst. of Health, Bethesda, Md., USA
SO Gonadotropins, Proc. Workshop Conf., 3rd (1968), 355-65. Editor(s): Rosembert, Eugenia. Publisher: Geron-X, Inc., Los Altos, Calif.
CODEN: 20VAA3
DT Conference
LA English

L6 ANSWER 30 OF 34 CA COPYRIGHT 2001 ACS
AN 70:75797 CA
TI Radioimmunologic determinations of luteinizing hormone throughout the menstrual cycle
AU Jaffe, Robert B.; Midgley, A. Rees, Jr.
CS Med. Center, Univ. of Michigan, Ann Arbor, Mich., USA
SO Ovary, Proc. Annu. Symp. Physiol. Pathol. Hum. Reprod., 2nd (1968), Meeting Date 1966, 27-46. Editor(s): Mack, Harold C.. Publisher: Charles C. Thomas, Springfield, Ill.
CODEN: 20LZAS
DT Conference
LA English

L6 ANSWER 31 OF 34 CA COPYRIGHT 2001 ACS
AN 70:9101 CA
TI Biological properties of three ovulation inducers, stilbestrol, clomiphene, and F 6066
AU Watnick, Arthur S.; Neri, R. O.
CS Biol. Res. Div., Schering Corp., Bloomfield, N. J., USA
SO Acta Endocrinol. (Copenhagen) (1968), 59(4), 611-21
CODEN: ACENA7
DT Journal
LA English

L6 ANSWER 32 OF 34 CA COPYRIGHT 2001 ACS
AN 67:10183 CA
TI The efficacy of two nonsteroidal antifertility agents after topical administration of rats
AU Coppola, John A.; Ball, J. L.
CS Lederle Labs., American Cyanamid Co., Pearl River, N. Y., USA
SO J. Reprod. Fertil. (1967), 13(2), 373-4
CODEN: JRPFA4
DT Journal
LA English

L6 ANSWER 33 OF 34 CA COPYRIGHT 2001 ACS
AN 66:84539 CA
TI Mechanism of antiimplantation action of clomiphene
AU Prasad, M. R. N.; Kalra, S. P.
CS Univ. Delhi, Delhi, India
SO J. Reprod. Fertil. (1967), 13(1), 59-66

CODEN: JRPFA4
DT Journal
LA English

L6 ANSWER 34 OF 34 CA COPYRIGHT 2001 ACS
AN 66:44066 CA
TI Compounds interfering with ovum implantation and development. II. Synthetic estrogens and antiestrogens
AU Morris, John McLean; Van Wagenen, Gertrude; McCann, Thomas; Jacob, Dennis
CS Sch. of Med., Yale Univ., New Haven, Conn., USA
SO Fertil. Steril. (1967), 18(1), 18-34
CODEN: FESTAS
DT Journal
LA English

=> d 16 6 9 18 19 20 all

L6 ANSWER 6 OF 34 CA COPYRIGHT 2001 ACS
AN 111:187732 CA
TI Induction and promotion of .gamma.-glutamyltranspeptidase-positive foci in the liver of female rats treated with ethinylestradiol, clomiphene, tamoxifen and their associations
AU Ghia, M.; Mereto, E.
CS Inst. Pharmacol., Univ. Genoa, Genoa, I-16132, Italy
SO Cancer Lett. (Shannon, Irel.) (1989), 46(3), 195-202
CODEN: CALEDQ; ISSN: 0304-3835
DT Journal
LA English
CC 2-3 (Mammalian Hormones)
AB The objective of the present study was to det. whether a short exposure (6 wk) to high doses of ethinylestradiol (EE) could not only promote but also initiate hepatocarcinogenesis, and whether two antiestrogens, clomiphene (C) and tamoxifen (T), could influence EE activity. 2-Acetylaminofluorene (AAF), which has been shown to produce rat liver hyperplastic lesions characterized by the presence of estrogen receptors, was used either as a promoter to test for initiating activity, or as an initiator to test for promoting activity. Putative preneoplastic lesions were identified by means of a pos. .gamma.-glutamyltranspeptidase (GGT) reaction. The results revealed that when administered alone in female Sprague-Dawley rats, not only EE, but also C and T were clearly active in both initiating and promoting the development of GGT-pos. foci. Moreover, in rats of the same strain treated with EE + C or EE + T a significant increase in the incidence of GGT foci demonstrated the occurrence of an additive effect in terms of both initiating and promoting activity. Fischer 344 rats were more susceptible than Sprague-Dawley rats to promotion by EE, C, and T, but any substantial evidence of an additive effect was absent when the two antiestrogens were administered in assocn. with the estrogen.
ST liver carcinogenesis ethinylestradiol; estrogen liver carcinoma clomiphene tamoxifen
IT Estrogens
RL: BIOL (Biological study)
(and antagonists, liver carcinogenesis induction and promotion by)
IT Liver, neoplasm

(hepatoma, estrogens and antiestrogens induction and promotion of)
IT **Contraceptives**
(oral, liver carcinogenesis induction and promotion by estrogenic component of)
IT 57-63-6, Ethinyl estradiol
RL: BIOL (Biological study)
(liver carcinogenesis induction and promotion by antiestrogens and)
IT **911-45-5**, Clomiphene 10540-29-1, Tamoxifen
RL: BIOL (Biological study)
(liver carcinogenesis induction and promotion by ethinylestradiol and)

L6 ANSWER 9 OF 34 CA COPYRIGHT 2001 ACS
AN 108:16889 CA
TI **Contraceptive** compositions comprising a progesterone antagonist and a blocker of progesterone activity
PA Yeda Research and Development Co. Ltd., Israel
SO Israeli, 6 pp.
CODEN: ISXXAQ
DT Patent
LA English
IC ICM A61K045-06
CC 2-3 (Mammalian Hormones)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	IL 68222	A1	19870227	IL 1983-68222	19830324
	US 4670426	A	19870602	US 1984-672716	19841119
PRAI	IL 1983-68222		19830324		
	US 1984-581023		19840216		

AB A pharmaceutical compn. having postcoital **contraceptive** activity contains an effective quantity of a progesterone antagonist selected from aminoglutethimide (AG), 22-azacholesterol, clomiphene, and 17.beta.-hydroxy-7.alpha.-methylandrost-5-en-3-one, in combination with a blocker of progesterone activity selected from triamcinolone acetonide (TA), triamcinolone base, cortisone, and fluocinolone as active ingredients. A compn. contains AG 100 and TA 5 mg/kg. Adult cycling rats were given a compn. contg. AG 10 and TA 5 mg/kg/day in 2 doses s.c. during 3 consecutive days starting 3 days after fertilization. Abortion was obsd. 14 days after fertilization.
ST **contraceptive** progesterone antagonist; aminoglutethimide triamcinolone acetonide **contraceptive**
IT Abortion
(from aminoglutethimide-triamcinolone mixts.)
IT **Contraceptives**
(progesterone antagonists)
IT 57-83-0, Progesterone, biological studies
RL: BIOL (Biological study)
(antagonists, as postcoital **contraceptives**)
IT 111876-67-6 111876-68-7 111876-69-8
RL: BIOL (Biological study)
(as postcoital **contraceptive**)
IT 125-84-8 **911-45-5**, Clomiphene 3915-24-0, 22-Azacholesterol 50880-57-4
RL: BIOL (Biological study)
(**contraceptive** compns. contg. progesterone activity blocker and, postcoital)
IT 53-06-5 76-25-5, Triamcinolone acetonide 124-94-7 356-12-7
RL: BIOL (Biological study)
(**contraceptive** compns. contg. progesterone antagonists and, postcoital)

L6 ANSWER 18 OF 34 CA COPYRIGHT 2001 ACS
AN 79:210 CA
TI Antifertility effect of three new clomiphene analogs on animals
AU Basu, Jayasree
CS Reprod. Biol. Div., Indian Inst. Exp. Med., Calcutta, India
SO Jap. J. Exp. Med. (1973), 43(1), 9-15
CODEN: JJEMAG
DT Journal
LA English
CC 1-5 (Pharmacodynamics)
AB Orally administered 1-[p-[2-diethylamino)ethoxy]phenyl]-1,2-diphenyl-2-nitroethylene citrate (EIPW 111) (I) [21708-94-1] (3-4 mg/kg) was an effective **contraceptive** in mice, rats, and rabbits in both precoital and postcoital stages whereas 1-[p-[2-(dimethylamino)ethoxy]phenyl]-1,2-diphenyl-2-nitroethylene citrate (EIPW 113) (II) [40297-41-4] (3 mg/kg) and 1-[p-[2-(diethylamino)ethoxy]phenyl]-1,2-diphenylethylene citrate (EIPW 103) (III) [40297-42-5] were not effective. A single oral dose of clomiphene citrate (IV) [**50-41-9**] (3 mg/kg) showed 100% antifertility effect in mice only at the preimplantation phase. I had no effect on male fertility. I showed estrogenic activity.
ST **contraceptive** oral ethylene deriv; estrogenic hormone ethylene deriv; fertility inhibitor ethylene deriv; antifertility clomiphene analog
IT **Contraceptives**
(oral, clomiphene analogs as)
IT 21708-94-1
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(contracepive activity of)
IT 19957-53-0 40529-32-6
RL: BIOL (Biological study)
(**contraceptive** activity in reaction to)
IT **50-41-9**
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(**contraceptive** activity of, analogs in relation to)

L6 ANSWER 19 OF 34 CA COPYRIGHT 2001 ACS
AN 78:47800 CA
TI 2-[p-2-Chloro-1,2-diphenylvinyl)phenoxy]triethylamine **contraceptive**
IN Holtkamp, Dorsey E.
PA Richardson-Merrell Inc.
SO Fr. Demande, 7 pp.
CODEN: FRXXBL
DT Patent
LA French
IC A61K; C07C
CC 63-6 (Pharmaceuticals)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 2110234		19720707		
PRAI US 1970-78259		19701005		

GI For diagram(s), see printed CA Issue.
AB The title compd. (I) (cisclomiphene) has **contraceptive** activity and minimal side effects. Thus, capsules contg. 20 mg I dihydrogen citrate were prepd.
ST clomiphene **contraceptive**
IT **Contraceptives**
(oral, cis-clomiphene as)

IT **15690-55-8** 41689-89-8
RL: BIOL (Biological study)
(**contraceptive**)

L6 ANSWER 20 OF 34 CA COPYRIGHT 2001 ACS
AN 78:20205 CA
TI Oral **contraceptive** formulations
IN MacGregor, Alexander Hamilton; Holtkamp, Dorsey Emil
PA Richardson-Merrell Inc.
SO Ger. Offen., 19 pp.
CODEN: GWXXBX
DT Patent
LA German
IC A61K
CC 63-6 (Pharmaceuticals)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2218016	A	19721109	DE 1972-2218016	19720414
	ZA 7201930	A	19721227	ZA 1972-1930	19720321
	FR 2133862	A5	19721201	FR 1972-13627	19720418
	FR 2133862	B1	19750620		
	BE 782321	A1	19720816	BE 1972-116498	19720419
PRAI	US 1971-135430		19710419		

AB The progestagen-free title prepns. leading only to normal menstruational bleeding and a min. of spotting, consisted of an estrogen, e.g. ethynylestradiol (I), and one of its antagonists, e.g. cis-clomiphene citrate (II). Thus, a **contraceptive** capsule (administered once daily) consisted of I 0.1, II 10.0, lactose 172.6, Terra alba 21.5, Mg stearate 4.3, and corn starch 21.5 mg.
ST oral **contraceptive** clomiphene citrate; ethynylestradiol oral **contraceptive**; estradiol ethynyl oral **contraceptive**; estrogen antagonist **contraceptive**
IT **Contraceptives**
(oral, estrogens and clomiphene estrogen antagonists as)
IT 56-53-1 57-63-6 72-33-3 84-17-3 152-43-2 517-18-0 569-57-3 5635-50-7
RL: BIOL (Biological study)
(oral **contraceptives**, clomiphene derivs. in)
IT **50-41-9** 64-96-0 1847-63-8 2624-43-3 3063-72-7 5189-40-2 5863-35-4 **7619-53-6** 10540-29-1 13002-65-8 15140-23-5
RL: BIOL (Biological study)
(oral **contraceptives**, estrogenic compds. in)

=> d 16 34 33 32 29 28 23 21 all

L6 ANSWER 34 OF 34 CA COPYRIGHT 2001 ACS
AN 66:44066 CA
TI Compounds interfering with ovum implantation and development. II. Synthetic estrogens and antiestrogens
AU Morris, John McLean; Van Wagenen, Gertrude; McCann, Thomas; Jacob, Dennis
CS Sch. of Med., Yale Univ., New Haven, Conn., USA
SO Fertil. Steril. (1967), 18(1), 18-34
CODEN: FESTAS
DT Journal
LA English
CC 4 (Hormones)
AB cf. preceding abstr. Clomiphene (I), p-hydroxypropiophenone, U 11,555A, U
11,100A, and ORF-3858 (2-methyl-3-ethyl-4-phenyl-.DELTA.4-cyclohexenecarboxylic acid) were evaluated for possible postcoital

contraceptive effects in rabbits and macaque monkeys. These compds. decreased the no. of decidual cells at the implantation site, caused degeneration with vacuolization of the cytoplasm and disintegration of the cell nuclei during uterine symplasma, and caused areas of hemorrhage and necrosis at the junction of maternal and fetal tissues, indicating that the mechanism of action of these weakly estrogenic compds. involved alteration of the implantation sites. Only ORF-3858 showed no evidence of teratogenicity and was an effective postcoital **contraceptive** agent in the macaque monkey when given for 6 days at 2 mg./kg. following pos. mating. 16 references.

ST POSTCOITAL **CONTRACEPTIVES**; CLOMIPHENE POSTCOITAL CONTRACEPTION; OVUM IMPLANTATION INTERFERENCE

IT Uterus
(egg implantation site damage by estrogens and their inhibitors)

IT Eggs
(implantation of, inhibition by estrogens and estrogen inhibitors)

IT 7698-97-7
RL: BIOL (Biological study)
(as **contraceptive** (postcoital))

IT 64-96-0 70-70-2 **911-45-5** 1847-63-8
RL: BIOL (Biological study)
(egg implantation inhibiting and teratogenic activity of)

L6 ANSWER 33 OF 34 CA COPYRIGHT 2001 ACS

AN 66:84539 CA

TI Mechanism of antiimplantation action of clomiphene

AU Prasad, M. R. N.; Kalra, S. P.

CS Univ. Delhi, Delhi, India

SO J. Reprod. Fertil. (1967), 13(1), 59-66
CODEN: JRPFA4

DT Journal

LA English

CC 15 (Pharmacodynamics)

AB Clomiphene (I) prevented implantation of blastocysts when administered to rats by gavage at 0.3 mg./kg./day before implantation, probably due either to a direct blastotoxic effect of the chem. or to elimination of blastocysts from the uterus. I administered orally to rats on day 9, days 9 and 10, or days 9, 10, and 11 after mating reduced the percentage of rats showing blastocysts from 100 to 37.5% and reduced the no. of blastocysts recovered from the uteri of treated rats, depending on the dose and the time interval allowed for action of the compd. Ligation of uterine horns at the cervical end before treatment resulted in recovery of normal nos. of blastocysts in 75% of the rats, indicating that the blastocysts are expelled from nonligated uteri. Estradiol (1 .gamma./day), injected s.c. 6, 24, and 48 hrs. after the 1st administration of I, failed to cause implantation of blastocysts in ligated uteri, suggesting that failure of implantation following I administration may be due to increased motility of the uterus resulting in expulsion of the blastocysts or to its antiesterogenic and (or) antihistaminic activity which prevents preimplantation changes in the uterus normally initiated by exogenously administered estrogen. I had no direct cytolytic effects on the blastocysts. 27 references.

IT Uterus
(motility of, clomiphene effect on)

IT **Contraceptives**
(oral, clomiphene as, uterus motility response to)

IT **911-45-5**

RL: BIOL (Biological study)
(uterus motility response to, in implantation inhibition by)

L6 ANSWER 32 OF 34 CA COPYRIGHT 2001 ACS
AN 67:10183 CA
TI The efficacy of two nonsteroidal antifertility agents after topical administration of rats
AU Coppola, John A.; Ball, J. L.
CS Lederle Labs., American Cyanamid Co., Pearl River, N. Y., USA
SO J. Reprod. Fertil. (1967), 13(2), 373-4
CODEN: JRPFA4
DT Journal
LA English
CC 15 (Pharmacodynamics)
AB 2-[p-(6 - Methoxy - 2 - phenylinden - 3 - yl)phenoxy]triethylamine - HCl (U11555A) and 1-[p-[.beta.-(diethylamino)ethoxy]phenyl] -1,2-diphenyl-2-chloroethylene citrate) (MRL-41) produced a dose-dependent decrease in the incidence of pregnancy in rats following single or daily administration either orally or topically. MRL-41 was 10-fold more potent than U11555A after single or daily treatment either orally or topically. MRL-41, 0.1 mg./kg., and U11555A, 1 mg./kg./day, completely terminated pregnancy. The antifertility action elicited by these compds. apparently was all or none in nature.
ST PHENOXYTRIETHYLAMINES ANTIFERTILITY AGENTS; ANTIFERTILITY AGENTS PHENOXYTRIETHYLAMINES; CHLOROETHYLENES ANTIFERTILITY AGENTS
IT **Contraceptives**
(1-[p-[.beta.-(diethylamino)ethoxy]phenyl]-1,2-diphenyl-2-chloroethylene citrate and 2-[p-(6-methoxy-2-phenylinden-3-yl)phenoxy]triethylamine hydrochloride as)
IT 64-96-0
RL: BIOL (Biological study)
(as **contraceptive**, 1-[p-[.beta.-(diethylamino)ethoxy]phenyl]-1,2-diphenyl-2-chloroethylene citrate and)
IT **50-41-9**
RL: BIOL (Biological study)
(as **contraceptive**, 2-[p-(6-methoxy-2-phenylinden-3-yl)phenoxy]triethylamine hydrochloride and)

L6 ANSWER 29 OF 34 CA COPYRIGHT 2001 ACS
AN 70:112103 CA
TI Effect of oral **contraceptives** on plasma follicle-stimulating hormone
AU Cargille, C. M.; Ross, Griff T.; Rayford, Phillip L.
CS Nat. Cancer Inst., Nat. Inst. of Health, Bethesda, Md., USA
SO Gonadotropins, Proc. Workshop Conf., 3rd (1968), 355-65. Editor(s): Rosembert, Eugenia. Publisher: Geron-X, Inc., Los Altos, Calif.
CODEN: 20VAA3
DT Conference
LA English
CC 4 (Hormones)
AB Data are given on plasma FSH and LH detd. daily in 8 women, aged 18-23, with regular menstruation. Estns. were done by radioimmunoassay. A curve is interpreted for daily FSH levels on 1 woman in a normal menstrual cycle. FSH reached a peak at about the 14th day of the cycle. In the luteal phase of the cycle, plasma progesterone showed a 29-fold rise over the follicular level. Curves are also given for plasma FSH and LH in normal menstrual cycles and during administration of the oral **contraceptive** Enovid E (I). Since I is a mixt. of norethynodrel and mestranol, the sep. effects of these 2 steroids were not detd. The main effect of I was to obliterate cyclic changes in FSH and LH. To the extent that ovulation depends upon changes in FSH and LH, it is probable

that the **contraceptive** action of I is mainly a suppression of pituitary secretion of gonadotropins with a resulting inhibition of ovulation. The effects of clomiphene (II), either racemic or as the individual isomers, was detd. In 50-mg. doses of II given twice a day on days 5, 6, and 7 of the menstrual cycle, there were no consistent changes in either FSH or LH. However, peculiar variations in posttreatment cycles suggested that II may have been retained in the body with delayed effects. High doses of II, such as 300 mg., suppressed FSH and LH in postmenopausal women. Data on pituitary FSH and LH in women who died suddenly at different stages of the menstrual cycle are interpreted.

ST oral **contraceptives** plasma LH; plasma LH oral **contraceptives**; **contraceptives** oral plasma LH; luteinizing hormone antiovulatory drugs; antiovulatory drugs plasma LH; FSH plasma oral **contraceptives**

IT Blood plasma
(follicle-stimulating hormone in, Enovid effect on)

IT Follicle-stimulating hormone
(in blood plasma, Enovid effect on)

IT **911-45-5**
RL: BIOL (Biological study)
(gonadotropin metabolism response to)

IT 68-23-5
RL: BIOL (Biological study)
(mixts. with mestranol, follicle-stimulating hormone in blood plasma in response to)

IT 72-33-3
RL: BIOL (Biological study)
(mixts. with norethynodrel, follicle-stimulating hormone in blood plasma in response to)

L6 ANSWER 28 OF 34 CA COPYRIGHT 2001 ACS

AN 72:51491 CA

TI Effects of clomiphene and gonadotropin on ovarian function in women with steroid-induced iatrogenic anovulation

AU Zanartu, Juan; Pupkin, Marcos; Rosenberg, David; Mendez, Gustavo; Stone, Sergio; Guerrero, Rodolfo; Puga, Juan

CS Hosp. Clin. J. Joaquin Aguirre, Santiago de Chile, Chile

SO Rev. Chil. Obstet. Ginecol. (1968), 33(6), 345-52
CODEN: RCOBA4

DT Journal

LA Spanish

CC 4 (Hormones and Related Substances)

AB Clomiphene citrate (100 mg daily for 7 days) and (or) chorionic gonadotropin (5000 IU, i.m. for 3-4 days) were given to 2 groups of 18 women each suffering from spontaneous anovulation or anovulation due to **contraceptive** treatment with medroxyprogesterone acetate (I). The combined treatment more frequently led to the appearance of pos. signs suggesting an ovulatory response than either substance given alone, but the rate of pregnancies was low. Ovarian biopsy carried out in 4 women receiving the combined treatment and I revealed the presence of luteinized follicles in 3 and of corpus lute um in only 1 case.

ST clomiphene ovarian function; ovarian function clomiphene; gonadotropins chorionic pregnancy; chorionic gonadotropins pregnancy; ovulation inducers

IT Amenorrhea
(chorionic gonadotropin and clomiphene in treatment of)

IT Ovulation
(chorionic gonadotropin and clomiphene induction of, in amenorrhea)

IT Gonadotropic hormones
RL: BIOL (Biological study)
(chorionic, ovulation response to, in amenorrhea and spontaneous anovulation)
IT 71-58-9
RL: BIOL (Biological study)
(ovulation inhibition by, chorionic gonadotropin and chomiphene effect on)
IT **50-41-9**
RL: BIOL (Biological study)
(ovulation response to, in amenorrhea and spontaneous anovulation)

L6 ANSWER 23 OF 34 CA COPYRIGHT 2001 ACS
AN 76:81565 CA
TI Effect of ten **contraceptive** drugs on voluntary alcohol consumption in albino rats
AU Eriksson, Kalervo
CS Res. Lab., State Alcohol Monop. (Alko), Helsinki, Finland
SO Arukoru Kenkyu (1971), 6(1), 9-11
CODEN: JJSAAG
DT Journal
LA English
CC 2 (Hormone Pharmacology)
AB The **contraceptives** clomiphene citrate (I citrate) [**50-41-9**] (7), mestranol [72-33-3] (36), and 17-ethynylestradiol [57-63-6] (4 .mu.g/100 g/day in diet) caused a statistically significant redn. of voluntary Et alc. [64-17-5] intake in female rats.
ST ethanol intake **contraceptive**; clomiphene voluntary alc intake; mestranol voluntary alc intake; ethynylestradiol voluntary alc intake
IT **Contraceptives**
(ethyl alcohol dependence inhibition by)
IT 64-17-5, biological studies
RL: BIOL (Biological study)
(dependence on, **contraceptives** inhibition of)
IT **50-41-9** 57-63-6 72-33-3
RL: BIOL (Biological study)
(ethyl alcohol dependence inhibition by)

L6 ANSWER 21 OF 34 CA COPYRIGHT 2001 ACS
AN 77:52319 CA
TI Fertility-preventing compositions
IN Holtkamp, Dorsey Emil; Petrow, Vladimir
PA Richardson-Merrell Inc.
SO Ger. Offen., 19 pp.
CODEN: GWXXBX
DT Patent
LA German
IC A61K
CC 63-6 (Pharmaceuticals)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2149281	A	19720406	DE 1971-2149281	19711002
	ZA 7106118	A	19720531	ZA 1971-6118	19710913
	GB 1326528	A	19730815	GB 1971-43764	19710920
	IL 37772	A1	19750425	IL 1971-37772	19710923
	AU 7134060	A1	19730405	AU 1971-34060	19710930
	CA 963806	A1	19750304	CA 1971-124085	19710930
	BE 773518	A1	19720131	BE 1971-108949	19711005
	FR 2110233	A1	19720602	FR 1971-35858	19711005
	FR 2110233	A5	19720602		
PRAI	US 1970-78258		19701005		

AB The title product is a mixt. of a progestagen with an antiestrogenic

compd. E.g., a tablet contains quingestanol acetate 0.3, cis-clomiphene citrate 10, sucrose 67.5, lactose 109.2, starch 25, Mg stearate 3 mg and cornstarch to give 320 mg. Capsules were prepd. similarly.
ST antifertility compn progestagen; estrogen antifertility compn; quingestanol antifertility compn
IT **Contraceptives**
(oral, clomiphene citrate and quingestanol acetate as)
IT 3000-39-3
RL: BIOL (Biological study)
(**contraceptive**, with clomiphene citrate)
IT **7619-53-6**
RL: BIOL (Biological study)
(**contraceptive**, with quingestanol acetate)

=> s l4 and l5

L7 8 L4 AND L5

=> d l7 1-8

L7 ANSWER 1 OF 8 CA COPYRIGHT 2001 ACS
AN 107:2382 CA
TI The influence of various monooxygenase inducers on rat liver microsomal chrysene oxidation
AU Jacob, J.; Karcher, W.; Grimmer, G.; Schmoldt, A.; Hamann, M.
CS Biochem. Inst. Environ. Carcinog., Ahrensburg, 2070, Fed. Rep. Ger.
SO Polynucl. Aromat. Hydrocarbons: Chem., Charact. Carcinog., Int. Symp., 9th (1986), Meeting Date 1984, 417-26. Editor(s): Cooke, Marcus; Dennis, Anthony J. Publisher: Battelle Press, Columbus, Ohio.
CODEN: 55SUAC
DT Conference
LA English

L7 ANSWER 2 OF 8 CA COPYRIGHT 2001 ACS
AN 94:83931 CA
TI 2-Benzoyl-3-phenylbenzothiophene (or benzothiophene oxide)derivatives
PA Lilly, Eli, and Co., USA
SO Israeli, 56 pp.
CODEN: ISXXAQ
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	IL 50413	A1	19800530	IL 1976-50413	19760905
	AU 7617408	A1	19780309	AU 1976-17408	19760902
	AU 509682	B2	19800522		
	CA 1064031	A1	19791009	CA 1976-263897	19761021
	GB 1572506	A	19800730	GB 1976-44200	19761025
	ES 452737	A1	19780101	ES 1976-452737	19761026
	RO 70768	P	19821026	RO 1976-88226	19761026
	SE 7611954	A	19770429	SE 1976-11954	19761027
	SE 427035	B	19830228		
	SE 427035	C	19830609		
	DK 7604845	A	19770429	DK 1976-4845	19761027
	JP 52053852	A2	19770430	JP 1976-129998	19761027
	JP 61000344	B4	19860108		
	ZA 7606442	A	19780628	ZA 1976-6442	19761027
	CH 626360	A	19811113	CH 1976-13553	19761027
	NL 7611972	A	19770502	NL 1976-11972	19761028
	FR 2329270	A1	19770527	FR 1976-32513	19761028

	FR 2329270	B1	19790727		
	DD 127463	C	19770928	DD 1976-195510	19761028
	AT 7608007	A	19790315	AT 1976-8007	19761028
	AT 352709	B	19791010		
	CS 196328	P	19800331	CS 1976-6973	19761028
	PL 109366	B1	19800531	PL 1976-193328	19761028
	US 4075227	A	19780221	US 1976-743819	19761122
PRAI	US 1975-626009		19751028		

L7 ANSWER 3 OF 8 CA COPYRIGHT 2001 ACS
AN 90:151974 CA
TI 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
IN Jones, Charles David; Suarez, Tulio
PA Lilly, Eli, and Co., USA
SO U.S., 22 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4133814	A	19790109	US 1976-724203	19760917
	JP 52053851	A2	19770430	JP 1976-121787	19761008
	JP 61000343	B4	19860108		
	HU 21379	O	19811128	HU 1976-EI707	19761015
	HU 179012	B	19820828		
	CA 1090795	A1	19801202	CA 1976-263844	19761021
	ES 452695	A1	19771116	ES 1976-452695	19761025
	ES 452694	A1	19771116	ES 1976-452694	19761025
	SU 701539	D	19791130	SU 1976-2414465	19761025
	GB 1570610	A	19800702	GB 1976-44188	19761025
	AU 7619005	A1	19780504	AU 1976-19005	19761026
	SU 764610	D	19800915	SU 1976-2414462	19761026
	RO 70769	P	19821026	RO 1976-88224	19761026
	DK 7604848	A	19770429	DK 1976-4848	19761027
	DK 152045	B	19880125		
	DK 152045	C	19880620		
	SE 7611955	A	19770429	SE 1976-11955	19761027
	SE 426945	B	19830221		
	SE 426945	C	19830602		
	ZA 7606440	A	19780628	ZA 1976-6440	19761027
	PL 107979	B1	19800331	PL 1976-193308	19761027
	IL 50773	A1	19800331	IL 1976-50773	19761027
	PL 114190	B1	19810131	PL 1976-212113	19761027
	CH 635336	A	19830331	CH 1976-13556	19761027
	BE 847719	A1	19770428	BE 1976-1007725	19761028
	NL 7611975	A	19770502	NL 1976-11975	19761028
	FR 2329271	A1	19770527	FR 1976-32514	19761028
	FR 2329271	B1	19790727		
	DD 127461	C	19770928	DD 1976-195508	19761028
	AT 7608008	A	19791215	AT 1976-8008	19761028
	AT 357520	B	19800710		
	CS 205046	P	19810430	CS 1976-6974	19761028
	CH 635582	A	19830415	CH 1982-139	19820111
	CH 634316	A	19830131	CH 1982-255	19820114
	DK 8502658	A	19850613	DK 1985-2658	19850613
PRAI	US 1975-626010		19751028		
	CH 1976-13556		19761027		
	DK 1976-4848		19761027		

L7 ANSWER 4 OF 8 CA COPYRIGHT 2001 ACS
AN 88:37602 CA
TI Derivatives of 2-aroyl-3-phenylbenzothiophenes and of 2-aroyl-3-

phenylbenzothiophene 1-oxides with antifertility activity
IN Jones, Charles David; Suarez, Tulio
PA Lilly, Eli, and Co., USA
SO Belg., 43 pp.
CODEN: BEXXAL
DT Patent
LA French
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	BE 847718	A1	19770428	BE 1976-1007724	19761028
	AU 7617408	A1	19780309	AU 1976-17408	19760902
	AU 509682	B2	19800522		
	CA 1064031	A1	19791009	CA 1976-263897	19761021
	GB 1572506	A	19800730	GB 1976-44200	19761025
	ES 452737	A1	19780101	ES 1976-452737	19761026
	RO 70768	P	19821026	RO 1976-88226	19761026
	SE 7611954	A	19770429	SE 1976-11954	19761027
	SE 427035	B	19830228		
	SE 427035	C	19830609		
	DK 7604845	A	19770429	DK 1976-4845	19761027
	JP 52053852	A2	19770430	JP 1976-129998	19761027
	JP 61000344	B4	19860108		
	ZA 7606442	A	19780628	ZA 1976-6442	19761027
	CH 626360	A	19811113	CH 1976-13553	19761027
	NL 7611972	A	19770502	NL 1976-11972	19761028
	FR 2329270	A1	19770527	FR 1976-32513	19761028
	FR 2329270	B1	19790727		
	DD 127463	C	19770928	DD 1976-195510	19761028
	AT 7608007	A	19790315	AT 1976-8007	19761028
	AT 352709	B	19791010		
	CS 196328	P	19800331	CS 1976-6973	19761028
	PL 109366	B1	19800531	PL 1976-193328	19761028
	US 4075227	A	19780221	US 1976-743819	19761122
PRAI	US 1975-626009		19751028		

L7 ANSWER 5 OF 8 CA COPYRIGHT 2001 ACS
AN 87:102155 CA
TI Benzothiophene derivatives
IN Jones, Charles David; Suarez, Tulio
PA Lilly, Eli, and Co., USA
SO Ger. Offen., 56 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2647864	A1	19770512	DE 1976-2647864	19761022
	DE 2647864	C2	19850425		
	AU 7617408	A1	19780309	AU 1976-17408	19760902
	AU 509682	B2	19800522		
	CA 1064031	A1	19791009	CA 1976-263897	19761021
	GB 1572506	A	19800730	GB 1976-44200	19761025
	ES 452737	A1	19780101	ES 1976-452737	19761026
	RO 70768	P	19821026	RO 1976-88226	19761026
	SE 7611954	A	19770429	SE 1976-11954	19761027
	SE 427035	B	19830228		
	SE 427035	C	19830609		
	DK 7604845	A	19770429	DK 1976-4845	19761027
	JP 52053852	A2	19770430	JP 1976-129998	19761027
	JP 61000344	B4	19860108		
	ZA 7606442	A	19780628	ZA 1976-6442	19761027

	CH 626360	A	19811113	CH 1976-13553	19761027
	NL 7611972	A	19770502	NL 1976-11972	19761028
	FR 2329270	A1	19770527	FR 1976-32513	19761028
	FR 2329270	B1	19790727		
	DD 127463	C	19770928	DD 1976-195510	19761028
	AT 7608007	A	19790315	AT 1976-8007	19761028
	AT 352709	B	19791010		
	CS 196328	P	19800331	CS 1976-6973	19761028
	PL 109366	B1	19800531	PL 1976-193328	19761028
	US 4075227	A	19780221	US 1976-743819	19761122
PRAI	US 1975-626009		19751028		

L7 ANSWER 6 OF 8 CA COPYRIGHT 2001 ACS
AN 87:84806 CA
TI 2-Phenyl-3-aroylbenzothiophenes and 2-phenyl-3-aroylbenzothiophene 1-oxides
IN Jones, Charles David; Suarez, Tulio
PA Lilly, Eli, and Co., USA
SO Ger. Offen., 81 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2647907	A1	19770512	DE 1976-2647907	19761022
	DE 2647907	C2	19850124		
	JP 52053851	A2	19770430	JP 1976-121787	19761008
	JP 61000343	B4	19860108		
	HU 21379	O	19811128	HU 1976-EI707	19761015
	HU 179012	B	19820828		
	CA 1090795	A1	19801202	CA 1976-263844	19761021
	ES 452695	A1	19771116	ES 1976-452695	19761025
	ES 452694	A1	19771116	ES 1976-452694	19761025
	SU 701539	D	19791130	SU 1976-2414465	19761025
	GB 1570610	A	19800702	GB 1976-44188	19761025
	AU 7619005	A1	19780504	AU 1976-19005	19761026
	SU 764610	D	19800915	SU 1976-2414462	19761026
	RO 70769	P	19821026	RO 1976-88224	19761026
	DK 7604848	A	19770429	DK 1976-4848	19761027
	DK 152045	B	19880125		
	DK 152045	C	19880620		
	SE 7611955	A	19770429	SE 1976-11955	19761027
	SE 426945	B	19830221		
	SE 426945	C	19830602		
	ZA 7606440	A	19780628	ZA 1976-6440	19761027
	PL 107979	B1	19800331	PL 1976-193308	19761027
	IL 50773	A1	19800331	IL 1976-50773	19761027
	PL 114190	B1	19810131	PL 1976-212113	19761027
	CH 635336	A	19830331	CH 1976-13556	19761027
	BE 847719	A1	19770428	BE 1976-1007725	19761028
	NL 7611975	A	19770502	NL 1976-11975	19761028
	FR 2329271	A1	19770527	FR 1976-32514	19761028
	FR 2329271	B1	19790727		
	DD 127461	C	19770928	DD 1976-195508	19761028
	AT 7608008	A	19791215	AT 1976-8008	19761028
	AT 357520	B	19800710		
	CS 205046	P	19810430	CS 1976-6974	19761028
	CH 635582	A	19830415	CH 1982-139	19820111
	CH 634316	A	19830131	CH 1982-255	19820114
	DK 8502658	A	19850613	DK 1985-2658	19850613
PRAI	US 1975-626010		19751028		
	CH 1976-13556		19761027		

DK 1976-4848 19761027

L7 ANSWER 7 OF 8 CA COPYRIGHT 2001 ACS
AN 81:105516 CA
TI Thieno[2,3-g]indazoles
IN Houlihan, William J.
PA Sandoz-Wander, Inc.
SO U.S., 4 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 3816437	A	19740611	US 1972-317519	19721222

L7 ANSWER 8 OF 8 CA COPYRIGHT 2001 ACS
AN 76:136190 CA
TI Antifertility effects in rats of some compounds related to azasteroids
AU Gaind, B.; Mathur, V. S.
CS Dep. Pharmacol., Postgrad. Inst. Med. Educ. Res., Chandigarh, India
SO J. Reprod. Fert. (1971), 27(3), 459-60
CODEN: JRPFA4
DT Journal
LA English

=> d l7 1-8 All

L7 ANSWER 1 OF 8 CA COPYRIGHT 2001 ACS
AN 107:2382 CA
TI The influence of various monooxygenase inducers on rat liver microsomal chrysene oxidation
AU Jacob, J.; Karcher, W.; Grimmer, G.; Schmoldt, A.; Hamann, M.
CS Biochem. Inst. Environ. Carcinog., Ahrensburg, 2070, Fed. Rep. Ger.
SO Polynucl. Aromat. Hydrocarbons: Chem., Charact. Carcinog., Int. Symp., 9th (1986), Meeting Date 1984, 417-26. Editor(s): Cooke, Marcus; Dennis, Anthony J. Publisher: Battelle Press, Columbus, Ohio.
CODEN: 55SUAC
DT Conference
LA English
CC 4-6 (Toxicology)
GI



I

AB The incubation of chrysene (I) liver microsomes from female rats caused I oxidn. in position 3,4; male microsomes caused I oxidn. in position 3,4 and 1,2. Pretreatment of the rats with polycyclic arom. hydrocarbons, N-contg. heterocyclic compds., pesticides, or drugs usually enhanced oxidn. is position 1,2. Lung microsomes of male rats oxidized I in position 3,4 only; pretreatment of the rats with the xenobiotics usually did not affect the oxidn. rates. The pretreatment of rats with **contraceptives** reduced I metab. rates in males and enhanced the

rates in females.
ST liver microsome chrysene oxidn sex
IT Sex
(chrysene oxidn. by liver microsomes response to xenobiotics in relation to)
IT Lung
(chrysene oxidn. by microsomes of, pretreatment with xenobiotics effect
on)
IT Liver
(microsomes of, chrysene oxidn. by, pretreatment with xenobiotics effect on, sex in relation to)
IT Microsome
(of liver and lung, chrysene oxidn. by, pretreatment with xenobiotics effect on, sex in relation to)
IT 50-29-3, DDT, biological studies 50-32-8, Benzo[a]pyrene, biological studies 53-70-3, Dibenz[a,h]anthracene 57-41-0, Diphenylhydantoin 57-63-6, Ethinylestradiol 58-89-9, .gamma.-Hexachlorocyclohexane 87-86-5, Pentachlorophenol 189-92-4, 10-Azabenzo[a]pyrene 195-19-7, Benzo[c]phenanthrene **205-43-6**, Benzo[b]naphtho[1,2-d]thiophene 225-11-6, Benz[a]acridine 225-51-4, Benz[c]acridine 226-36-8, Dibenz[a,h]acridine **239-35-0**, Benzo[b]naphtho[2,1-d]thiophene 797-63-7, Levonorgestrel 6533-00-2
RL: BIOL (Biological study)
(chrysene oxidn. by microsomes of liver and lung response to pretreatment with, sex in relation to)
IT 28622-71-1 28622-72-2
RL: FORM (Formation, nonpreparative)
(formation of, by microsomes of liver and lung, pretreatment with xenobiotics effect on, sex in relation to)
IT 218-01-9, Chrysene
RL: RCT (Reactant)
(oxidn. of, by microsomes of liver and lung, pretreatment with xenobiotics effect on, sex in relation to)

L7 ANSWER 2 OF 8 CA COPYRIGHT 2001 ACS
AN 94:83931 CA
TI 2-Benzoyl-3-phenylbenzothiophene (or benzothiophene oxide)derivatives
PA Lilly, Eli, and Co., USA
SO Israeli, 56 pp.
CODEN: ISXXAQ
DT Patent
LA English
IC C07D333-56; C07D409-12
CC 27-8 (Heterocyclic Compounds (One Hetero Atom))
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	IL 50413	A1	19800530	IL 1976-50413	19760905
	AU 7617408	A1	19780309	AU 1976-17408	19760902
	AU 509682	B2	19800522		
	CA 1064031	A1	19791009	CA 1976-263897	19761021
	GB 1572506	A	19800730	GB 1976-44200	19761025
	ES 452737	A1	19780101	ES 1976-452737	19761026
	RO 70768	P	19821026	RO 1976-88226	19761026
	SE 7611954	A	19770429	SE 1976-11954	19761027
	SE 427035	B	19830228		
	SE 427035	C	19830609		
	DK 7604845	A	19770429	DK 1976-4845	19761027
	JP 52053852	A2	19770430	JP 1976-129998	19761027
	JP 61000344	B4	19860108		
	ZA 7606442	A	19780628	ZA 1976-6442	19761027
	CH 626360	A	19811113	CH 1976-13553	19761027

	NL 7611972	A	19770502	NL 1976-11972	19761028
	FR 2329270	A1	19770527	FR 1976-32513	19761028
	FR 2329270	B1	19790727		
	DD 127463	C	19770928	DD 1976-195510	19761028
	AT 7608007	A	19790315	AT 1976-8007	19761028
	AT 352709	B	19791010		
	CS 196328	P	19800331	CS 1976-6973	19761028
	PL 109366	B1	19800531	PL 1976-193328	19761028
	US 4075227	A	19780221	US 1976-743819	19761122
PRAI	US 1975-626009		19751028		

GI



I



II

AB Benzothiophenes I (R, R1 = H, OH, alkoxy; R2 = H, Cl, Br, OH, alkoxy; R3 = H, pyrrolidinoethoxy; n = 0, 1) were prepd. Thus, acylation of II with 4-MeOC6H4COCl gave 70% I (R = R1 = R3 = H, R2 = 4-MeO, n = 0). The latter compd. showed antifertility activity on rats at 1 mg/day s.c.; II was prepd. by treating BrCH2COPh with PhSH and cyclizing PhSCH2COPh with polyphosphoric acid.

ST benzoylphenylbenzothiophene antifertility prepn; benzothiophene benzoylphenyl antifertility prepn

IT **Contraceptives**
(benzoylphenylbenzothiophenes)

IT 100-66-3, reactions
RL: RCT (Reactant)
(acylation of)

IT 98-88-4 100-07-2 122-01-0 618-46-2 21615-34-9
RL: RCT (Reactant)
(acylation of benzothiophene with)

IT 586-38-9
RL: RCT (Reactant)
(chlorination of)

IT 108-98-5, reactions
RL: RCT (Reactant)
(condensation of, bromoacetophenone)

IT 15570-12-4
RL: RCT (Reactant)
(condensation of, with bromoacetophenone)

IT 70-11-1
RL: RCT (Reactant)
(condensation of, with thiophenol)

IT 6305-04-0
RL: RCT (Reactant)
(condensation of, with thiophenone)

IT 99-76-3
RL: RCT (Reactant)

(etherification of)
IT 137-43-9
RL: RCT (Reactant)
(etherification of hydroxybenzoate with)
IT **14315-12-9P** 63762-92-5P 63762-94-7P 63763-12-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and acylation of)
IT 1711-05-3P 63763-05-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and acylation of benzothiophene with)
IT 63762-95-8P 63762-96-9P 63762-97-0P 63762-98-1P 63762-99-2P
63763-00-8P 63763-01-9P 63763-02-0P 63763-03-1P 63763-07-5P
63763-08-6P 63763-09-7P 63763-11-1P 63763-15-5P 63763-21-3P
63763-25-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and antifertility activity of)
IT 63763-24-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and antifertility of)
IT 23343-13-7P 30762-02-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and chlorination of)
IT 16222-10-9P 63762-91-4P 63762-93-6P 63763-18-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and cyclization of)
IT 63763-06-4P 63763-10-0P 63763-20-2P 63763-22-4P 63763-23-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and demethylation of)
IT 63763-04-2P 63763-17-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and hydrolysis of)
IT 6136-67-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and imination of)
IT 63763-13-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and neutralization of)
IT 63763-14-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and salt formation of)
IT 63763-16-6
RL: RCT (Reactant)
(reaction of, rhodanine)
IT 141-84-4
RL: RCT (Reactant)
(reaction of, with Ph methoxyphenyl ketimine)
IT 2398-37-0
RL: RCT (Reactant)
(reaction of, with benzonitrile)
IT 100-47-0, reactions
RL: RCT (Reactant)
(reaction of, with bromoanisole)
IT 7250-67-1
RL: RCT (Reactant)
(reaction of, with hydroxyphenylbenzothiophene)

L7 ANSWER 3 OF 8 CA COPYRIGHT 2001 ACS
AN 90:151974 CA
TI 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
IN Jones, Charles David; Suarez, Tulio
PA Lilly, Eli, and Co., USA
SO U.S., 22 pp.
CODEN: USXXAM

DT Patent
LA English
IC C07D409-10
NCL 260326550A
CC 27-9 (Heterocyclic Compounds (One Hetero Atom))
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4133814	A	19790109	US 1976-724203	19760917
	JP 52053851	A2	19770430	JP 1976-121787	19761008
	JP 61000343	B4	19860108		
	HU 21379	O	19811128	HU 1976-EI707	19761015
	HU 179012	B	19820828		
	CA 1090795	A1	19801202	CA 1976-263844	19761021
	ES 452695	A1	19771116	ES 1976-452695	19761025
	ES 452694	A1	19771116	ES 1976-452694	19761025
	SU 701539	D	19791130	SU 1976-2414465	19761025
	GB 1570610	A	19800702	GB 1976-44188	19761025
	AU 7619005	A1	19780504	AU 1976-19005	19761026
	SU 764610	D	19800915	SU 1976-2414462	19761026
	RO 70769	P	19821026	RO 1976-88224	19761026
	DK 7604848	A	19770429	DK 1976-4848	19761027
	DK 152045	B	19880125		
	DK 152045	C	19880620		
	SE 7611955	A	19770429	SE 1976-11955	19761027
	SE 426945	B	19830221		
	SE 426945	C	19830602		
	ZA 7606440	A	19780628	ZA 1976-6440	19761027
	PL 107979	B1	19800331	PL 1976-193308	19761027
	IL 50773	A1	19800331	IL 1976-50773	19761027
	PL 114190	B1	19810131	PL 1976-212113	19761027
	CH 635336	A	19830331	CH 1976-13556	19761027
	BE 847719	A1	19770428	BE 1976-1007725	19761028
	NL 7611975	A	19770502	NL 1976-11975	19761028
	FR 2329271	A1	19770527	FR 1976-32514	19761028
	FR 2329271	B1	19790727		
	DD 127461	C	19770928	DD 1976-195508	19761028
	AT 7608008	A	19791215	AT 1976-8008	19761028
	AT 357520	B	19800710		
	CS 205046	P	19810430	CS 1976-6974	19761028
	CH 635582	A	19830415	CH 1982-139	19820111
	CH 634316	A	19830131	CH 1982-255	19820114
	DK 8502658	A	19850613	DK 1985-2658	19850613
PRAI	US 1975-626010		19751028		
	CH 1976-13556		19761027		
	DK 1976-4848		19761027		

GI



I

AB 3-Benzoylthiophenes I [R = OH; R1 = H, OH, alkoxy, OCH2CH2NR3R4 (R3 and R4
are independently alkyl or NR3R4 = pyrrolidino, piperidino, hexamethylenimino, morpholino); R2 = H] and acid addn. salts of I (R1 = OCH2CH2NR3R4) exhibited antifertility and anti-tumor activity and were prepd. by benzoylation of 2-phenylbenzothiophenes. PhCOCH2Br, PhSH, and pyridine was refluxed 6 h, the PhCOCH2SPh obtained was heated with polyphosphoric acid to yield 2-phenylbenzothiophene, and acylation of the product by 4-MeOC6H4COCl and AlCl3 gave I (R = R1 = H, R2 = OMe).

ST **contraceptive** benzoylphenylbenzothiophene prepn; benzothiophene benzoyl prepn antifertility; tumor benzoylphenylbenzothiophene prepn

IT **Contraceptives**
Neoplasm inhibitors
(2-phenyl-3-benzoylbenzothiophenes)

IT 74-54-4 100-66-3, reactions 2674-04-6
RL: RCT (Reactant)
(acylation by benzothiophenecarbonyl chloride deriv.)

IT 98-88-4
RL: RCT (Reactant)
(acylation of benzothiophene deriv. by)

IT 100-07-2 63675-91-2
RL: RCT (Reactant)
(acylation of benzothiophenes by)

IT 69731-94-8 69731-95-9 69731-96-0 69731-97-1 69923-40-6
RL: RCT (Reactant)
(antifertility activity of)

IT 63675-90-1
RL: RCT (Reactant)
(conversion to acid chlorides, for acylation of benzothiophene deriv.)

IT 79-37-8
RL: RCT (Reactant)
(cyclocondensation reaction with thiophenol deriv.)

IT 27884-09-9P 63676-23-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and acylation of, by benzoyl chloride deriv.)

IT 63676-27-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and acylation of, by benzoyl chloride derivs.)

IT **1207-95-0P** 63675-74-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and acylation of, by benzoyl chlorides)

IT 63676-25-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and anti-tumor activity of)

IT 63675-76-3P 63675-82-1P 63675-83-2P 63675-84-3P 63675-86-5P
63675-88-7P 63675-93-4P 63675-95-6P 63675-98-9P 63675-99-0P
63676-00-6P 63676-03-9P 63676-11-9P 63676-12-0P 63676-21-1P
63676-28-8P 63712-59-4P 63712-61-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and antifertility activity of)

IT 63676-07-3P 63676-09-5P 63676-13-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and antifertility and anti-tumor activity of)

IT 16222-10-9P 21875-72-9P 33192-00-6P 63675-73-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and cyclization of, isomerization in)

IT 63675-78-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and cyclocondensation reaction of, decarboxylation in)

IT 63676-24-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and deprotection of)

IT 69862-12-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and oxidative elimination reaction of)
IT 63675-79-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of, with thionyl chloride)
IT 63675-77-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and ring cleavage of, by chloroacetic acid deriv.)
IT 63675-89-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and sapon. of)
IT 63676-04-0P 63676-19-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and O-alkylation of, by aminoethyl chloride deriv.)
IT 63675-97-8P 63676-05-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and O-alkylation of, by aminoethyl chlorides)
IT 63676-22-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and O-protection of)
IT 63675-75-2P 63675-81-0P 63675-85-4P 63675-87-6P 63675-92-3P
63675-94-5P 63675-96-7P 63676-01-7P 63676-06-2P 63676-20-0P
63676-26-6P 63712-60-7P 69731-93-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
IT 63675-80-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, and acylation of benzenes by)
IT 63675-90-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, and acylation of benzothiophene deriv. by)
IT 4755-72-0
RL: RCT (Reactant)
(ring cleavage of dioxodihydrobenzothiophene deriv. by)
IT 108-98-5, reactions
RL: RCT (Reactant)
(substitution reaction of, with phenacyl bromides)
IT 15570-12-4
RL: RCT (Reactant)
(substitution reaction with phenethyl bromide deriv.)
IT 70-11-1 536-38-9
RL: RCT (Reactant)
(substitution reaction with thiophenol)
IT 2632-13-5
RL: RCT (Reactant)
(substitution reaction with thiophenols)
IT 99-76-3
RL: RCT (Reactant)
(O-alkylation by aminoethyl chloride deriv.)
IT 96-79-7 1932-03-2 2205-31-4 5050-41-9
RL: RCT (Reactant)
(O-alkylation of (hydroxybenzoyl)benzothiophene deriv. by)
IT 100-35-6
RL: RCT (Reactant)
(O-alkylation of (hydroxyphenyl)benzothiophene deriv. by)
IT 7250-67-1
RL: RCT (Reactant)
(O-alkylation of hydroxybenzoate deriv. by)

L7 ANSWER 4 OF 8 CA COPYRIGHT 2001 ACS
AN 88:37602 CA
TI Derivatives of 2-aroyl-3-phenylbenzothiophenes and of 2-aroyl-3-

phenylbenzothiophene 1-oxides with antifertility activity
IN Jones, Charles David; Suarez, Tulio
PA Lilly, Eli, and Co., USA
SO Belg., 43 pp.
CODEN: BEXXAL
DT Patent
LA French
IC C07D
CC 27-9 (Heterocyclic Compounds (One Hetero Atom))
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	BE 847718	A1	19770428	BE 1976-1007724	19761028
	AU 7617408	A1	19780309	AU 1976-17408	19760902
	AU 509682	B2	19800522		
	CA 1064031	A1	19791009	CA 1976-263897	19761021
	GB 1572506	A	19800730	GB 1976-44200	19761025
	ES 452737	A1	19780101	ES 1976-452737	19761026
	RO 70768	P	19821026	RO 1976-88226	19761026
	SE 7611954	A	19770429	SE 1976-11954	19761027
	SE 427035	B	19830228		
	SE 427035	C	19830609		
	DK 7604845	A	19770429	DK 1976-4845	19761027
	JP 52053852	A2	19770430	JP 1976-129998	19761027
	JP 61000344	B4	19860108		
	ZA 7606442	A	19780628	ZA 1976-6442	19761027
	CH 626360	A	19811113	CH 1976-13553	19761027
	NL 7611972	A	19770502	NL 1976-11972	19761028
	FR 2329270	A1	19770527	FR 1976-32513	19761028
	FR 2329270	B1	19790727		
	DD 127463	C	19770928	DD 1976-195510	19761028
	AT 7608007	A	19790315	AT 1976-8007	19761028
	AT 352709	B	19791010		
	CS 196328	P	19800331	CS 1976-6973	19761028
	PL 109366	B1	19800531	PL 1976-193328	19761028
	US 4075227	A	19780221	US 1976-743819	19761122
PRAI	US 1975-626009		19751028		

GI



I

AB Benzoylbenzothiophenes I (R = H, 4-OMe, 4-OH, 4-cyclopentyloxy, 3-OMe, 3-OH, 2-OMe, 2-OH, 3-Cl, 4-Cl; R1 = H, OMe, OH) and some S-oxides and related compds. (20 compds.) were prepd. Thus BrCH2Bz was treated with PhSH and PhSCH2Bz cyclized with polyphosphoric acid to give 3-phenylbenzothiophene, which was Friedel-Crafts acylated with 4-MeOC6H4COCl to give 70% I (R = 4-OMe; R1 = H), which at 1 mg/day s.c. in rats totally prevented pregnancies.

ST benzoylbenzothiophene; **contraceptive** benzoylbenzothiophene; benzothiophene benzoyl

IT **Contraceptives**
(benzoylbenzothiophenes)

IT 122-01-0 618-46-2
RL: RCT (Reactant)
(Friedel-Crafts acylation of benzothiophene derivs. by)

IT 98-88-4 100-07-2 21615-34-9

RL: RCT (Reactant)
(Friedel-Crafts acylation of benzothiophenes by)

IT 63762-94-7
RL: RCT (Reactant)
(aminoalkylation of)

IT 586-38-9
RL: RCT (Reactant)
(chlorination of)

IT **14315-12-9P** 63762-92-5P 63763-13-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and Friedel-Crafts acylation of)

IT 1711-05-3P 63763-05-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and Friedel-Crafts acylation of benzothiophenes by)

IT 6136-67-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and amination of)

IT 30762-02-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and chlorination of)

IT 63762-96-9P 63762-98-1P 63763-00-8P 63763-02-0P 63763-03-1P
63763-07-5P 63763-09-7P 63763-11-1P 63763-15-5P 63763-21-3P
63763-24-6P 63763-25-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and **contraceptive** activity of)

IT 16222-10-9P 63762-91-4P 63762-93-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and cyclization of)

IT 63763-06-4P 63763-10-0P 63763-20-2P 63763-23-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and demethylation of)

IT 63763-04-2P 63763-17-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and hydrolysis of)

IT 63763-16-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of, with rhodamine)

IT 23343-13-7P 63762-94-7P 63763-18-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

IT 63762-99-2P 63763-01-9P 63763-08-6P 63763-22-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn., demethylation, and **contraceptive** activity of)

IT 63762-95-8P 63762-97-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn., oxidn., and **contraceptive** activity of)

IT 2398-37-0
RL: RCT (Reactant)
(reaction of, with benzonitrile)

IT 108-98-5, reactions 15570-12-4
RL: RCT (Reactant)
(reaction of, with bromoacetophenone)

IT 100-47-0, reactions
RL: RCT (Reactant)
(reaction of, with bromoanisole)

IT 99-76-3
RL: RCT (Reactant)
(reaction of, with cyclopentyl bromide)

IT 81-88-9
RL: RCT (Reactant)
(reaction of, with diphenyliminomethanes)

IT 137-43-9
RL: RCT (Reactant)

(reaction of, with hydroxybenzoate)
IT 7250-67-1
RL: RCT (Reactant)
(reaction of, with hydroxyphenylbenzothiophene)
IT 6305-04-0
RL: RCT (Reactant)
(reaction of, with methoxythiophenol)
IT 70-11-1
RL: RCT (Reactant)
(reaction of, with thiophenols)

L7 ANSWER 5 OF 8 CA COPYRIGHT 2001 ACS
AN 87:102155 CA
TI Benzothiophene derivatives
IN Jones, Charles David; Suarez, Tulio
PA Lilly, Eli, and Co., USA
SO Ger. Offen., 56 pp.
CODEN: GWXXBX
DT Patent
LA German
IC C07D333-56
CC 27-9 (Heterocyclic Compounds (One Hetero Atom))
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2647864	A1	19770512	DE 1976-2647864	19761022
	DE 2647864	C2	19850425		
	AU 7617408	A1	19780309	AU 1976-17408	19760902
	AU 509682	B2	19800522		
	CA 1064031	A1	19791009	CA 1976-263897	19761021
	GB 1572506	A	19800730	GB 1976-44200	19761025
	ES 452737	A1	19780101	ES 1976-452737	19761026
	RO 70768	P	19821026	RO 1976-88226	19761026
	SE 7611954	A	19770429	SE 1976-11954	19761027
	SE 427035	B	19830228		
	SE 427035	C	19830609		
	DK 7604845	A	19770429	DK 1976-4845	19761027
	JP 52053852	A2	19770430	JP 1976-129998	19761027
	JP 61000344	B4	19860108		
	ZA 7606442	A	19780628	ZA 1976-6442	19761027
	CH 626360	A	19811113	CH 1976-13553	19761027
	NL 7611972	A	19770502	NL 1976-11972	19761028
	FR 2329270	A1	19770527	FR 1976-32513	19761028
	FR 2329270	B1	19790727		
	DD 127463	C	19770928	DD 1976-195510	19761028
	AT 7608007	A	19790315	AT 1976-8007	19761028
	AT 352709	B	19791010		
	CS 196328	P	19800331	CS 1976-6973	19761028
	PL 109366	B1	19800531	PL 1976-193328	19761028
	US 4075227	A	19780221	US 1976-743819	19761122
PRAI	US 1975-626009		19751028		

GI



I

AB Benzoylbenzothiophenes I (R = H, OH; R1 = H, OMe, OH; R2 = H, 4-OMe, 4-OH, 4-cyclopentyloxy, 3-OMe, 3-OH, 2-OH, 3-Cl, 4-Cl; R3 = H, pyrrolidinoethoxy) and S-oxides were prepd. Thus, PhCOCH2Br was treated with PhSH, PhCOCH2SPh cyclized with polyphosphoric acid, 3-phenylbenzothiophene acylated by 4-MeOC6H4COCl to give I (R = R1 = R3 = H, R2 = 4-OMe). I are **contraceptives**. Thus, I (R = R1 = R3 = H, R2 = 4-OMe), at 1 mg/day for 15 days, completely inhibited conception in rats.

ST benzothiophene benzoyl phenyl prepn; benzoylphenylbenzothiophene prepn **contraceptive**

IT **Contraceptives**
(2-benzoyl-3-phenylbenzothiophenes)

IT 98-88-4 100-07-2 122-01-0 618-46-2 21615-34-9
RL: RCT (Reactant)
(Friedel-Crafts acylation of benzothiophenes by)

IT 2398-37-0
RL: RCT (Reactant)
(Grignard reaction of, with benzonitrile)

IT 100-47-0, reactions
RL: RCT (Reactant)
(Grignard reaction of, with bromoanisole)

IT 7250-67-1
RL: RCT (Reactant)
(etherification of (hydroxyphenyl)benzothiophene deriv. by)

IT **14315-12-9P** 63763-13-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and Friedel-Crafts acylation of)

IT 1711-05-3P 63763-05-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and Friedel-Crafts acylation of benzothiophenes by)

IT 63763-19-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and Friedel-Crafts reaction of, with anisole)

IT 63762-96-9P 63762-98-1P 63762-99-2P 63763-00-8P 63763-02-0P 63763-03-1P 63763-07-5P 63763-09-7P 63763-11-1P 63763-15-5P 63763-21-3P 63763-24-6P 63763-25-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and **contraceptive** activity of)

IT 16222-10-9P 63762-91-4P 63762-93-6P 63763-18-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and cyclization of)

IT 63763-06-4P 63763-10-0P 63763-20-2P 63763-22-4P 63763-23-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and demethylation of)

IT 63762-94-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and etherification of, with 1-(2-chloroethyl)pyrrolidine)

IT 63763-04-2P 63763-17-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and hydrolysis of)

IT 6136-67-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of, with ammonia)
IT 63763-16-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of, with rhodanine)
IT 23343-13-7P 30762-02-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of, with thionyl chloride)
IT 63762-92-5P 63763-12-2P 63763-14-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
IT 63762-95-8P 63762-97-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn., S-oxidn., and **contraceptive** activity of)
IT 63763-01-9P 63763-08-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn., demethylation, and **contraceptive** activity of)
IT 99-76-3
RL: RCT (Reactant)
(reaction of, with cyclopentyl bromide)
IT 137-43-9
RL: RCT (Reactant)
(reaction of, with hydroxybenzoate ester)
IT 108-98-5, reactions 15570-12-4
RL: RCT (Reactant)
(reaction of, with phenacyl bromide)
IT 141-84-4
RL: RCT (Reactant)
(reaction of, with phenyl methoxyphenyl ketimine)
IT 586-38-9
RL: RCT (Reactant)
(reaction of, with thionyl chloride)
IT 70-11-1
RL: RCT (Reactant)
(reaction of, with thiophenol)
IT 6305-04-0
RL: RCT (Reactant)
(reaction of, with thiophenol deriv.)

L7 ANSWER 6 OF 8 CA COPYRIGHT 2001 ACS
AN 87:84806 CA
TI 2-Phenyl-3-aroylbenzothiophenes and 2-phenyl-3-aroylbenzothiophene 1-oxides
IN Jones, Charles David; Suarez, Tulio
PA Lilly, Eli, and Co., USA
SO Ger. Offen., 81 pp.
CODEN: GWXXBX
DT Patent
LA German
IC C07D333-56
CC 27-9 (Heterocyclic Compounds (One Hetero Atom))
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2647907	A1	19770512	DE 1976-2647907	19761022
	DE 2647907	C2	19850124		
	JP 52053851	A2	19770430	JP 1976-121787	19761008
	JP 61000343	B4	19860108		
	HU 21379	O	19811128	HU 1976-EI707	19761015
	HU 179012	B	19820828		
	CA 1090795	A1	19801202	CA 1976-263844	19761021
	ES 452695	A1	19771116	ES 1976-452695	19761025
	ES 452694	A1	19771116	ES 1976-452694	19761025

	SU 701539	D	19791130	SU 1976-2414465	19761025
	GB 1570610	A	19800702	GB 1976-44188	19761025
	AU 7619005	A1	19780504	AU 1976-19005	19761026
	SU 764610	D	19800915	SU 1976-2414462	19761026
	RO 70769	P	19821026	RO 1976-88224	19761026
	DK 7604848	A	19770429	DK 1976-4848	19761027
	DK 152045	B	19880125		
	DK 152045	C	19880620		
	SE 7611955	A	19770429	SE 1976-11955	19761027
	SE 426945	B	19830221		
	SE 426945	C	19830602		
	ZA 7606440	A	19780628	ZA 1976-6440	19761027
	PL 107979	B1	19800331	PL 1976-193308	19761027
	IL 50773	A1	19800331	IL 1976-50773	19761027
	PL 114190	B1	19810131	PL 1976-212113	19761027
	CH 635336	A	19830331	CH 1976-13556	19761027
	BE 847719	A1	19770428	BE 1976-1007725	19761028
	NL 7611975	A	19770502	NL 1976-11975	19761028
	FR 2329271	A1	19770527	FR 1976-32514	19761028
	FR 2329271	B1	19790727		
	DD 127461	C	19770928	DD 1976-195508	19761028
	AT 7608008	A	19791215	AT 1976-8008	19761028
	AT 357520	B	19800710		
	CS 205046	P	19810430	CS 1976-6974	19761028
	CH 635582	A	19830415	CH 1982-139	19820111
	CH 634316	A	19830131	CH 1982-255	19820114
	DK 8502658	A	19850613	DK 1985-2658	19850613
PRAI	US 1975-626010		19751028		
	CH 1976-13556		19761027		
	DK 1976-4848		19761027		

GI



I

AB Benzothiophenes I [R = H, OMe, OH; R1 = H, OMe, OH, pyrrolidinoethoxy, OCH2CH2NEt2, OAc, O2CEt, O2CBu, OBz, adamantylcarbonyloxy, O2COEt, Cl; R2 = H, OMe, OH, pyrrolidinoetoxy, piperidinoethoxy, hexamethyleniminoethoxy, OCH2CH2N(CHMe2)2] and the 1-oxide I (R = R1 = OH, R2 = H) were prepd. Thus BrCH2COPh was treated with PhSH in the presence of pyridine, PhSCH2COPh cyclized with polyphosphoric acid, 2-phenylbenzothiophene subjected to Friedel-Crafts acylation with 4-MeOC6H4COCl and I (R = R1 = H, R2 = OMe) demethylated with pyridine-HCl to give I (R = R1 = H, R2 = OH). I are fertility inhibitors. Thus I (R = R1 H, R2 = OH) as 1 mg/kg day s.c. in rats for 15 days completely inhibited fetus development.

ST benzothiophene benzoylphenyl; benzoylphenylbenzothiophene; **contraceptive** benzoylphenylbenzothiophene

IT **Contraceptives**
(benzoylphenylthiophenes)

IT 98-88-4
RL: RCT (Reactant)
(Friedel-Crafts acylation of benzothiophenes by)

IT 100-07-2
RL: RCT (Reactant)
(Friedel-Crafts acylation of phenylbenzothiophene by)
IT 100-66-3, reactions
RL: RCT (Reactant)
(Friedel-Crafts reaction of, with methoxybenzothiophenecarbonyl chloride)
IT 63675-90-1
RL: RCT (Reactant)
(chlorination of)
IT **1207-95-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and Fredel-Crafts acylation of)
IT 63675-74-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and Friedel-Crafts acylation of)
IT 63675-91-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and Friedel-Crafts acylation of phenylbenzothiophene by)
IT 63675-79-6P 63675-90-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and chlorination of)
IT 63675-76-3P 63675-82-1P 63675-84-3P 63675-86-5P 63675-88-7P
63675-93-4P 63675-95-6P 63675-99-0P 63676-00-6P 63676-07-3P
63676-09-5P 63676-11-9P 63676-13-1P 63676-14-2P 63676-15-3P
63676-16-4P 63676-17-5P 63676-18-6P 63676-21-1P 63676-28-8P
63712-59-4P 63712-61-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and **contraceptive** activity of)
IT 16222-10-9P 21875-72-9P 33192-00-6P 63675-73-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and cyclization of)
IT 63675-75-2P 63675-81-0P 63675-87-6P 63675-96-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and demethylation of)
IT 63675-85-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and demethylatuon of)
IT 63675-89-8P 63676-24-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and hydrolysis of)
IT 63675-78-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of, with acetic anhydride)
IT 63676-22-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of, with bromochloroacetophenone)
IT 63676-19-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of, with chloroethylpyrrolidine)
IT 63676-05-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of, with chloroethylpyrrolidine hydrochloride)
IT 63675-97-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of, with chloroethylpyrrolidinehydrochloride)
IT 63675-77-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of, with chlorophenylacetic acid)
IT 63675-91-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of, with chlorophenylbenzothiophene)
IT 63675-80-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of, with diphenylcadmium)
IT 63676-23-3P 63676-27-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of, with pyrrolidinoethoxybenzoyl chloride)
IT 27884-09-9P 63675-92-3P 63676-01-7P 63676-03-9P 63676-06-2P
63676-20-0P 63676-25-5P 63676-26-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
IT 63676-12-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn., acylation, and **contraceptive** activity of)
IT 63675-83-2P 63675-98-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn., demethylation, and **contraceptive** activity of)
IT 63676-04-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn., reaction with chloroethylpyrrolidine, and
contraceptive activity of)
IT 2674-04-6
RL: RCT (Reactant)
(reaction of, with benzothiophenecarbonyl chloride)
IT 4755-72-0
RL: RCT (Reactant)
(reaction of, with benzothiophenedione)
IT 108-98-5, reactions
RL: RCT (Reactant)
(reaction of, with bromoacetophenone)
IT 15570-12-4
RL: RCT (Reactant)
(reaction of, with bromomethoxyacetophenone)
IT 108-24-7
RL: RCT (Reactant)
(reaction of, with carboxycarbonylphenylacetic acid)
IT 99-76-3
RL: RCT (Reactant)
(reaction of, with chloroethylpyrrolidine hydrochloride)
IT 7250-67-1
RL: RCT (Reactant)
(reaction of, with hydroxybenzoate)
IT 100-35-6 536-38-9
RL: RCT (Reactant)
(reaction of, with hydroxyphenylbenzothiophene)
IT 74-54-4
RL: RCT (Reactant)
(reaction of, with methoxybenzothiophenecarbonyl chloride)
IT 70-11-1 2632-13-5
RL: RCT (Reactant)
(reaction of, with thiophenol)

L7 ANSWER 7 OF 8 CA COPYRIGHT 2001 ACS
AN 81:105516 CA
TI Thieno[2,3-g]indazoles
IN Houlihan, William J.
PA Sandoz-Wander, Inc.
SO U.S., 4 pp.
CODEN: USXXAM
DT Patent
LA English
IC C07D
NCL 260294800B
CC 28-11 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 27, 13

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3816437	A	19740611	US 1972-317519	19721222

GI For diagram(s), see printed CA Issue.

AB 4,5-Dihydro-3-(4-pyridyl)-2H-thieno[2,3-g]indazole (I), an effective fertility control agent when administered to animals s.c. at 50 mg 4 .times. a day, was prepd. Reaction of the thionaphthene (II) with 4-pyridinecarboxaldehyde gave the spiro compd. (III), which was cyclized with N2H4 to give I. Four addnl. prepns. of I were given.

ST thienoindazole pyridyl fertility control; pyridylthienoindazole fertility control; spirobenzothiophene oxirane cyclization hydrazine

IT **Contraceptives**
(dihydropyridylthienoindazole)

IT **13414-95-4**
RL: RCT (Reactant)
(bromination of)

IT 302-01-2, reactions
RL: RCT (Reactant)
(cyclization of, with dihydropyridylspiro[benzothioene-oxirane]one)

IT 53278-35-6
RL: RCT (Reactant)
(cyclization of, with hydrazine)

IT 53336-21-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and cyclization of, with hydrazine)

IT 53278-32-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and fertility control by)

IT 53278-33-4P 53278-34-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

IT 872-85-5
RL: RCT (Reactant)
(reaction of, with bromooxothionaphthene derivs.)

IT **2513-49-7**
RL: RCT (Reactant)
(reaction of, with pyridinecarboxaldehyde)

L7 ANSWER 8 OF 8 CA COPYRIGHT 2001 ACS

AN 76:136190 CA

TI Antifertility effects in rats of some compounds related to azasteroids

AU Gaind, B.; Mathur, V. S.

CS Dep. Pharmacol., Postgrad. Inst. Med. Educ. Res., Chandigarh, India

SO J. Reprod. Fert. (1971), 27(3), 459-60
CODEN: JRPFA4

DT Journal

LA English

CC 2 (Hormone Pharmacology)

AB 5-[(2-Chlorobenzylidene)amino]isoquinoline (I) [34616-48-3], 4-keto-4,5,6,7-tetrahydrothianaphthene [**13414-95-4**], and 9 other azasteroids were tested for antifertility effects in rats at an oral dose of 20 mg/kg body wt. from day 1 to day 7 of pregnancy, and I was 77.0% effective. These compds. did not show any toxic effects at the dose administered.

ST azasteroid antifertility effect; chlorobenzylideneaminoisoquinoline pregnancy

IT Azasteroids
RL: BIOL (Biological study)
(as **contraceptives**)

IT **Contraceptives**
(azasteroids as)

IT **13414-95-4** 19995-19-8 34616-48-3 35857-73-9

35857-74-0 35857-75-1 **35877-26-0**
RL: BIOL (Biological study)
(as **contraceptive**)

=> e danazol

```
E1          161     DANAUS/BI
E2            1     DANAVS/BI
E3          546 --> DANAZOL/BI
E4            2     DANAZOLE/BI
E5            6     DANB/BI
E6            1     DANB43/BI
E7            1     DANB454/BI
E8            8     DANBA/BI
E9            1     DANBAE/BI
E10           1     DANBAEGKONG/BI
E11           1     DANBAI/BI
E12           3     DANBAITE/BI
```

=> s e3

```
L8          546 DANAZOL/BI
```

=> e norgesterl

```
E1            4     NORGESTAMET/BI
E2            5     NORGESTEREL/BI
E3            0 --> NORGESTERL/BI
E4            2     NORGESTEROL/BI
E5            3     NORGESTERONE/BI
E6          154     NORGESTIMATE/BI
E7            1     NORGESTIMET/BI
E8            1     NORGESTIMMATE/BI
E9            1     NORGESTOMER/BI
E10         224     NORGESTOMET/BI
E11           5     NORGESTRAL/BI
E12           2     NORGESTRE/BI
```

=> s e1-e6

```
              4 NORGESTAMET/BI
              5 NORGESTEREL/BI
              0 NORGESTERL/BI
              2 NORGESTEROL/BI
              3 NORGESTERONE/BI
            154 NORGESTIMATE/BI
L9          167 (NORGESTAMET/BI OR NORGESTEREL/BI OR NORGESTERL/BI OR
NORGESTERO
                L/BI OR NORGESTERONE/BI OR NORGESTIMATE/BI)
```

=> s l8 and l5

```
L10          38 L8 AND L5
```

=> d l10 10-38

L10 ANSWER 10 OF 38 CA COPYRIGHT 2001 ACS
AN 118:198196 CA
TI Methods and formulations for use in inhibiting conception and in treating benign gynecological disorders
IN Spicer, Darcy Vernon; Pike, Malcolm Cecil

PA University of Southern California, USA
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9218107	A1	19921029	WO 1992-US2973	19920410
	W: CA, FI, NO, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
	US 5211952	A	19930518	US 1991-684612	19910412
	CA 2084891	AA	19921013	CA 1992-2084891	19920410
	CA 2084891	C	19990105		
	EP 538443	A1	19930428	EP 1992-910686	19920410
	EP 538443	B1	19971001		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
	AT 158717	E	19971015	AT 1992-910686	19920410
	ES 2109995	T3	19980201	ES 1992-910686	19920410
	NO 9204755	A	19930209	NO 1992-4755	19921209
	US 5340584	A	19940823	US 1993-952513	19930201
PRAI	US 1991-684612		19910412		
	WO 1992-US2973		19920410		

L10 ANSWER 11 OF 38 CA COPYRIGHT 2001 ACS
AN 116:121073 CA
TI Intrinsic estrogenicity of some progestagenic drugs
AU Markiewicz, Leszek; Hochberg, Richard B.; Gurpide, Erlio
CS Dep. Obstetr., Gynecol. Reprod. Sci., Mount Sinai Sch. Med., New York, NY,
10029, USA
SO J. Steroid Biochem. Mol. Biol. (1992), 41(1), 53-8
CODEN: JSBBEZ; ISSN: 0960-0760
DT Journal
LA English

L10 ANSWER 12 OF 38 CA COPYRIGHT 2001 ACS
AN 114:254029 CA
TI Compositions useful as **contraceptives** in males
IN Cohen, Michael
PA Neth.
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9100095	A1	19910110	WO 1990-NL90	19900626
	W: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MW, NL, NO, RO, SD, SE, SU, US				
	RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, DK, ES, FR, GA, GB, IT, LU, ML, MR, NL, SE, SN, TD, TG				
	IN 171596	A	19921121	IN 1990-MA495	19900620
	CA 2059138	AA	19901228	CA 1990-2059138	19900626
	AU 9059683	A1	19910117	AU 1990-59683	19900626
	AU 639467	B2	19930729		
	DD 297327	A5	19920109	DD 1990-342103	19900626
	EP 479867	A1	19920415	EP 1990-910521	19900626
	EP 479867	B1	19960515		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	DD 299619	A5	19920430	DD 1990-344095	19900626
	IL 94869	A1	19941007	IL 1990-94869	19900626

	JP 07507037	T2	19950803	JP 1990-510056	19900626
	AT 137970	E	19960615	AT 1990-910521	19900626
	CN 1048327	A	19910109	CN 1990-103286	19900627
	ZA 9005020	A	19910424	ZA 1990-5020	19900627
PRAI	US 1989-371794		19890627		
	WO 1990-N				

L90 19900626
OS MARPAT 114:254029

L10 ANSWER 13 OF 38 CA COPYRIGHT 2001 ACS
AN 112:240497 CA
TI Topical drug delivery systems containing **danazol**
IN Igarashi, Masao
PA Japan
SO Eur. Pat. Appl., 9 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 330786	A1	19890906	EP 1988-312441	19881230
	EP 330786	B1	19920318		
	R: CH, DE, FR, GB, IT, LI, NL, SE				
	JP 01221318	A2	19890904	JP 1988-45928	19880301
	JP 2590358	B2	19970312		
	US 4997653	A	19910305	US 1988-287481	19881220
	AU 8827479	A1	19890907	AU 1988-27479	19881222
	AU 618052	B2	19911212		
	CA 1312285	A1	19930105	CA 1988-587300	19881230
PRAI	JP 1988-45928		19880301		

L10 ANSWER 14 OF 38 CA COPYRIGHT 2001 ACS
AN 112:30760 CA
TI Antifertility effect of testosterone undecanoate in combination with **danazol** in male rats
AU Lu, Zhiliang; Yang, Baozhu; Fang, Ruiying
CS Zhejiang Branch, Chin. Acad. Med. Sci., Hangzhou, Peop. Rep. China
SO Zhongguo Yixue Kexueyuan Xuebao (1989), 11(3), 190-4
CODEN: CIHPDR; ISSN: 1000-503X
DT Journal
LA Chinese

L10 ANSWER 15 OF 38 CA COPYRIGHT 2001 ACS
AN 109:148321 CA
TI Vitamin B6 treatment of premenstrual syndrome
AU Brush, M. G.
CS Dep. Gynaecol., United Med. Dent. Sch., London, SE1 7EH, UK
SO Curr. Top. Nutr. Dis. (1988), 19(Clin. Physiol. Appl. Vitam. B-6), 363-79
CODEN: CTNDDU; ISSN: 0191-2453
DT Journal
LA English

L10 ANSWER 16 OF 38 CA COPYRIGHT 2001 ACS
AN 108:143647 CA
TI Effects of **danazol**, gonadotropin-releasing hormone agonist, and estrogen/progestogen combination on experimental endometriosis in the ovariectomized rat
AU Henig, Israel; Rawlins, Richard G.; Weinrib, Harry P.; Dmowski, W. Paul
CS Dep. Obstet. Gynecol., Rush Med. Coll., Chicago, IL, 60612, USA
SO Fertil. Steril. (1988), 49(2), 349-55
CODEN: FESTAS; ISSN: 0015-0282
DT Journal

LA English

L10 ANSWER 17 OF 38 CA COPYRIGHT 2001 ACS
AN 107:90031 CA
TI LH-RH analogs and steroids for male fertility regulation
AU Nieschlag, E.; Weinbauer, G. F.; Knuth, U. A.
CS Dep. Reprod. Med., Univ. Muenster, Muenster, D-440, Fed. Rep. Ger.
SO Serono Symp. Publ. Raven Press (1987), 36(Fertil. Regul. Today Tomorrow), 233-46
CODEN: SPRPDU; ISSN: 0733-897X
DT Journal; General Review
LA English

L10 ANSWER 18 OF 38 CA COPYRIGHT 2001 ACS
AN 106:13092 CA
TI Testis functions and sexual potential in langur monkey treated with a combination steroidal **contraceptive** formulation
AU Lohiya, N. K.; Sharma, O. P.; Sharma, R. C.
CS Dep. Zool., Univ. Rajasthan, Jaipur, 302 004, India
SO Contraception (1986), 34(4), 417-33
CODEN: CCPTAY; ISSN: 0010-7824
DT Journal
LA English

L10 ANSWER 19 OF 38 CA COPYRIGHT 2001 ACS
AN 105:165225 CA
TI A possible mechanism of action of **danazol** and an ethinylestradiol/norgestrel combination used as postcoital **contraceptive** agents
AU Rowlands, Sam; Kubba, Ali A.; Guillebaud, John; Bounds, Walli
CS Margaret Pyke Cent., London, W1V 5TW, UK
SO Contraception (1986), 33(6), 539-45
CODEN: CCPTAY; ISSN: 0010-7824
DT Journal
LA English

L10 ANSWER 20 OF 38 CA COPYRIGHT 2001 ACS
AN 104:200416 CA
TI The biochemistry of human endometrium after two regimens of postcoital contraception: a dl-norgestrel/ethinylestradiol combination or **danazol**
AU Kubba, Ali A.; White, John O.; Guillebaud, John; Elder, Murdoch G.
CS Margaret Pyke Cent., Hammersmith Hosp., London, W1V 5TW, UK
SO Fertil. Steril. (1986), 45(4), 512-16
CODEN: FESTAS; ISSN: 0015-0282
DT Journal
LA English

L10 ANSWER 21 OF 38 CA COPYRIGHT 2001 ACS
AN 103:48346 CA
TI Changes in the biochemical composition of semen following **danazol** plus testosterone enanthate administration to the langur monkey
AU Lohiya, N. K.; Sharma, R. C.; Sharma, O. P.
CS Dep. Zool., Univ. Rajasthan, Jaipur, 302 004, India
SO Contraception (1985), 31(4), 421-30
CODEN: CCPTAY; ISSN: 0010-7824
DT Journal
LA English

L10 ANSWER 22 OF 38 CA COPYRIGHT 2001 ACS
AN 103:773 CA
TI Reversible inhibition of testicular function by **danazol** plus testosterone enanthate in rabbit

AU Lohiya, N. K.; Sharma, O. P.
CS Dep. Zool., Univ. Rajastham, Jaipur, 302 004, India
SO Int. J. Fertil. (1984), 29(4), 228-33
CODEN: INJFA3; ISSN: 0020-725X
DT Journal
LA English

L10 ANSWER 23 OF 38 CA COPYRIGHT 2001 ACS
AN 102:17846 CA
TI Prostatic function in rabbit after administration of **danazol** plus testosterone enanthate
AU Lohiya, N. K.; Sharma, R. C.
CS Dep. Zool., Univ. Rajasthan, Jaipur, 302 004, India
SO Arch. Biol. (1984), 95(2), 215-22
CODEN: ABILAE; ISSN: 0003-9624
DT Journal
LA English

L10 ANSWER 24 OF 38 CA COPYRIGHT 2001 ACS
AN 101:944 CA
TI Reversible inhibition of spermatogenesis by **danazol** with combination of testosterone enanthate in rabbit
AU Lohiya, N. K.; Sharma, O. P.
CS Dep. Zool., Univ. Rajasthan, Jaipur, 302004, India
SO Andrologia (1984), 16(1), 72-5
CODEN: ANDRDQ; ISSN: 0303-4569
DT Journal
LA English

L10 ANSWER 25 OF 38 CA COPYRIGHT 2001 ACS
AN 95:36115 CA
TI Male contraception properties of a new synthetic steroid derivative (**Danazol**) in Rattus rattus Rufescens
AU Dixit, V. P.; Agrawal, Meera; Varma, Mira
CS Dep. Zool., Univ. Rajasthan, Jaipur, India
SO Endokrinologie (1981), 77(1), 30-8
CODEN: ENDKAC; ISSN: 0013-7251
DT Journal
LA English

L10 ANSWER 26 OF 38 CA COPYRIGHT 2001 ACS
AN 94:96387 CA
TI The use of androgens, androgen-**danazol** or androgen-progestogen combinations for the regulation of male fertility
AU Paulsen, C. Alvin; Leonard, J. M.; Bremner, W. J.
CS Sch. Med., Univ. Washington, Seattle, WA, USA
SO Endocrinol. Proc. Int. Congr. Endocrinol., 6th (1980), 516-19.
Editor(s):
Cumming, Ian A.; Funder, John W.; Mendelsohn, Frederick A. O. Publisher: Elsevier/N. Holland Biomed. Press, Amsterdam, Neth.
CODEN: 44YLAV
DT Conference; General Review
LA English

L10 ANSWER 27 OF 38 CA COPYRIGHT 2001 ACS
AN 90:16759 CA
TI Fertility in the rhesus monkey following long-term inhibition of ovarian function with **danazol**
AU Schane, H. Philip; Anzalone, Anthony J.; Potts, Gordon O.
CS Dep. Endocrinol., Sterling-Winthrop Res. Inst., Rensselaer, N. Y., USA
SO Fertil. Steril. (1978), 29(6), 692-4
CODEN: FESTAS; ISSN: 0015-0282
DT Journal

LA English

L10 ANSWER 28 OF 38 CA COPYRIGHT 2001 ACS
AN 88:115641 CA
TI **Danazol** effects on gonadotrop in basal levels and pituitary responsiveness to LH-RH in immature male rats
AU Pedroza, E.; Vilchez-Martinez, J. A.; Arimura, A.; Schally, A. V.
CS Endocr. Polypeptide Lab., VA Hosp., New Orleans, La., USA
SO Contraception (1978), 17(1), 61-9
CODEN: CCPTAY; ISSN: 0010-7824
DT Journal
LA English

L10 ANSWER 29 OF 38 CA COPYRIGHT 2001 ACS
AN 88:99610 CA
TI **Danazol** as a luteolytic agent
AU Wentz, Ann Colston; Sapp, Karan C.
CS Dep. Gynecol. Obstet., Johns Hopkins Univ. Sch. Med., Baltimore, Md., USA
SO Fertil. Steril. (1978), 29(1), 23-5
CODEN: FESTAS; ISSN: 0015-0282
DT Journal
LA English

L10 ANSWER 30 OF 38 CA COPYRIGHT 2001 ACS
AN 88:58728 CA
TI Chemical sterilization of male dogs: synergistic action of .alpha.-chlorohydrin (U-5897) with **danazol** on the testes and epididymides of dog
AU Dixit, V. P.
CS Dep. Zool., Univ. Rajasthan, Jaipur, India
SO Acta Eur. Fertil. (1977), 8(2), 167-73
CODEN: AEFTAA
DT Journal
LA English

L10 ANSWER 31 OF 38 CA COPYRIGHT 2001 ACS
AN 87:48420 CA
TI Evaluation of **danazol** as an oral **contraceptive**
AU Lauersen, Niels H.; Wilson, Kathleen H.
CS New York Hosp., Cornell Univ. Med. Cent., New York, N. Y., USA
SO Obstet. Gynecol. (Hagerstown, Md.) (1977), 50(1), 91-6
CODEN: OBGNAS
DT Journal
LA English

L10 ANSWER 32 OF 38 CA COPYRIGHT 2001 ACS
AN 87:48367 CA
TI Chemical sterilization: effects of **Danazol** administration on the testes and epididymides of male rabbit
AU Dixit, V. P.
CS Dep. Zool., Univ. Rajasthan, Jaipur, India
SO Acta Biol. Med. Ger. (1977), 36(1), 73-8
CODEN: ABMGAJ
DT Journal
LA English

L10 ANSWER 33 OF 38 CA COPYRIGHT 2001 ACS
AN 85:154410 CA
TI **Contraceptive** properties of **Danazol**
AU Colle, Michel L.; Greenblatt, Robert B.
CS Dep. Endocrinol., Med. Coll. Georgia, Augusta, Ga., USA
SO J. Reprod. Med. (1976), 17(2), 98-102
CODEN: JRPMAP

DT Journal
LA English

L10 ANSWER 34 OF 38 CA COPYRIGHT 2001 ACS
AN 85:57334 CA
TI Clinical trials in reversible male contraception. I. Combination of **danazol** plus testosterone
AU Paulsen, C. Alvin; Leonard, John M.
CS Sch. Med., Univ. Washington, Seattle, Wash., USA
SO Regul. Mech. Male Reprod. Physiol., Brook Lodge Workshop Probl. Reprod. Biol., 6th (1976), Meeting Date 1975, 197-211. Editor(s): Spilman, Charles H.; Lobl, Thomas J.; Kirton, Kenneth T. Publisher: Excerpta Med., Amsterdam, Neth.
CODEN: 33KEAO
DT Conference
LA English

L10 ANSWER 35 OF 38 CA COPYRIGHT 2001 ACS
AN 85:719 CA
TI Investigation of **Danazol** as a **contraceptive** agent
AU Wentz, Anne C.; Jones, Georgeanna Seegar; Sapp, Karan C.
CS Dep. Gynecol. Obstet., Johns Hopkins Hosp., Baltimore, Md., USA
SO Contraception (1976), 13(5), 619-30
CODEN: CCPTAY
DT Journal
LA English

L10 ANSWER 36 OF 38 CA COPYRIGHT 2001 ACS
AN 81:58611 CA
TI Pituitary gonadotropin inhibitory activity of **danazol**
AU Potts, Gordon O.; Beyler, Arthur L.; Schane, H. Philip
CS Sect. Endocrinol., Sterling-Winthrop Res. Inst., Rensselaer, N. Y., USA
SO Fert. Steril. (1974), 25(4), 367-72
CODEN: FESTAS
DT Journal
LA English

L10 ANSWER 37 OF 38 CA COPYRIGHT 2001 ACS
AN 81:58610 CA
TI Oral **contraceptive** activity of **danazol** in the rhesus monkey
AU Schane, H. Philip; Potts, Gordon O.
CS Sect. Endocrinol., Sterling-Winthrop Res. Inst., Rensselaer, N. Y., USA
SO Fert. Steril. (1974), 25(4), 363-6
CODEN: FESTAS
DT Journal
LA English

L10 ANSWER 38 OF 38 CA COPYRIGHT 2001 ACS
AN 79:61950 CA
TI **Danazol**-testosterone combination. Potentially effective means for reversible male contraception. Preliminary report
AU Skoglund, Rodney; Paulsen, C. Alvin
CS Dep. Med., Univ. Washington, Seattle, Wash., USA
SO Contraception (1973), 7(5), 357-65
CODEN: CCPTAY
DT Journal
LA English

=> d l10 1-9

L10 ANSWER 1 OF 38 CA COPYRIGHT 2001 ACS
AN 134:242693 CA
TI Compositions and methods for the prophylaxis and treatment of dysmenorrhea, endometriosis, and pre-term labor, using histidine
IN Peterson, John; Thomas, Peter G.
PA Cytos Pharamaceuticals, LLC, USA
SO U.S., 21 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6207696	B1	20010327	US 1998-153354	19980915

RE.CNT 2
RE
(1) Cox; CA
(2) Euro-Celtique S A; CA

L10 ANSWER 2 OF 38 CA COPYRIGHT 2001 ACS
AN 132:117610 CA
TI Gestagens, **danazol** and antiprogestogen in emergency contraception
AU Webb, A. M. C.
CS North Mersey Community (NHS) Trust, Liverpool, L2 1TA, UK
SO Int. Congr., Symp. Semin. Ser. (1997), 14(Contraception Today), 49-52
CODEN: ICGSEM; ISSN: 0969-2622
PB Parthenon Publishing Group Ltd.
DT Journal; General Review
LA English
RE.CNT 9
RE
(1) Glasier, A; N Engl J Med 1992, V327, P1041 MEDLINE
(2) Ho, P; Hum Reprod 1993, V8, P389 MEDLINE
(5) Van Look, P; Hum Reprod Update 1995, V1, P19 MEDLINE
(7) Webb, A; Br Med J 1992, V305, P927 MEDLINE
(8) Yuzpe, A; Fertil Steril 1982, V37, P508 MEDLINE
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 38 CA COPYRIGHT 2001 ACS
AN 129:153247 CA
TI Pharmaceutical preparations and methods for their regional administration
IN Ragavan, Vanaja V.; Dipiano, Gerianne M.
PA Femmepharma, USA
SO PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9832422	A1	19980730	WO 1998-US916	19980123
	W: AU, BR, CA, JP, KR, MX, US, US, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5993856	A	19991130	US 1997-971346	19971117
	AU 9859227	A1	19980818	AU 1998-59227	19980123
	EP 977555	A1	20000209	EP 1998-902614	19980123
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	US 1997-36727		19970124		
	US 1997-52578		19970715		
	US 1997-971346		19971117		

L10 ANSWER 4 OF 38 CA COPYRIGHT 2001 ACS
AN 128:266379 CA
TI Effects of dienogest, a synthetic steroid, on experimental endometriosis in rats
AU Katsuki, Yukio; Takano, Yukiko; Futamura, Yoshihiro; Shibutani, Yasunori; Aoki, Daisuke; Udagawa, Yasuhiro; Nozawa, Shiro
CS Toxicology Laboratory, Mochida Pharmaceutical Co. Ltd., Shizuoka, 426, Japan
SO Eur. J. Endocrinol. (1998), 138(2), 216-226
CODEN: EJOEEP; ISSN: 0804-4643
PB BioScientifica
DT Journal
LA English

L10 ANSWER 5 OF 38 CA COPYRIGHT 2001 ACS
AN 128:212540 CA
TI Application of emergency **contraceptives**
AU Tong, Jiansun; Cai, Reifeng
CS Jiangsu Family Planning Institute, Nanjing, 210029, Peop. Rep. China
SO Jiangsu Yiyao (1997), 23(11), 821
CODEN: CIYADX; ISSN: 0253-3685
PB Jiangsu Yiyao Bianjibu
DT Journal; General Review
LA Chinese

L10 ANSWER 6 OF 38 CA COPYRIGHT 2001 ACS
AN 127:341888 CA
TI Gestagens, **danazol** and antiprogestogen in emergency contraception
AU Webb, A. M. C.
CS North Mersey Community (NHS) Trust, Liverpool, L2 1TA, UK
SO Eur. J. Contracept. Reprod. Health Care (1997), 2(2), 127-129
CODEN: ECRCFK; ISSN: 1362-5187
PB Parthenon Publishing
DT Journal; General Review
LA English

L10 ANSWER 7 OF 38 CA COPYRIGHT 2001 ACS
AN 125:238862 CA
TI Depot medroxyprogesterone acetate versus an oral **contraceptive** combined with very-low-dose **danazol** for long-term treatment of pelvic pain associated with endometriosis
AU Vercellini, Paolo; De Giorgi, Olga; Oldani, Sabina; Cortesi, Ilenia; Panazza, Stefania; Crosignani, Pier Giorgo
CS Clinica Ostetrica e Ginecologica "Luigi Mangiagalli,", University Milano, Milan, 20122, Italy
SO Am. J. Obstet. Gynecol. (1996), 175(2), 396-401
CODEN: AJOGAH; ISSN: 0002-9378
DT Journal
LA English

L10 ANSWER 8 OF 38 CA COPYRIGHT 2001 ACS
AN 125:49599 CA
TI Is hormonal treatment efficacious in the management of ovarian cysts in women with histories of endometriosis?
AU Nezhat, Ceana H.; Nezhat, Farr; Borhan, Soheila; Seidman, Daniel S.; Nezhat, Camran R.
CS School Medicine, Mercer University, Macon, GA, USA
SO Hum. Reprod. (1996), 11(4), 874-877
CODEN: HUREEE; ISSN: 0268-1161
DT Journal

LA English

L10 ANSWER 9 OF 38 CA COPYRIGHT 2001 ACS
AN 123:189355 CA
TI Ovulation control by regulating nitric oxide levels
IN Garfield, Robert E.; Yallampalli, Chandrasekhar
PA Board of Regents, University of Texas System, USA
SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9515753	A1	19950615	WO 1994-US14133	19941208
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5470847	A	19951128	US 1993-165309	19931210
	AU 9513041	A1	19950627	AU 1995-13041	19941208
	US 5643944	A	19970701	US 1995-477189	19950607
	US 5721278	A	19980224	US 1995-477187	19950607
PRAI	US 1993-165309		19931210		
	WO 1994-US14133		19941208		

=> d l10 27 20 19 6 5 ALL

L10 ANSWER 27 OF 38 CA COPYRIGHT 2001 ACS
AN 90:16759 CA
TI Fertility in the rhesus monkey following long-term inhibition of ovarian function with **danazol**
AU Schane, H. Philip; Anzalone, Anthony J.; Potts, Gordon O.
CS Dep. Endocrinol., Sterling-Winthrop Res. Inst., Rensselaer, N. Y., USA
SO Fertil. Steril. (1978), 29(6), 692-4
CODEN: FESTAS; ISSN: 0015-0282
DT Journal
LA English
CC 2-5 (Hormone Pharmacology)
GI



I

AB **Danazol** (I) [17230-88-5] was previously reported to be an oral **contraceptive** in the rhesus monkey at doses of 200 and 400 mg/monkey/day for 90 days. I was an effective long-term inhibitor of ovarian function in the monkey. In the final 3 mo of a 27-mo period of

treatment at a dose of 400 mg/monkey/day, the drug continued to be an effective oral **contraceptive**. During the 27-mo treatment period, 3 of 7 monkeys were amenorrheic and the remaining had only 16 of the 109 expected menstrual cycles. Following the discontinuation of medication, all 7 monkeys conceived within 2 to 6 wk. One monkey aborted early in pregnancy and the remaining 6 delivered normal, healthy infants at term. Thus, following the discontinuation of long-term treatment with I in the monkey, there was rapid and complete return of normal ovarian function.

ST **Danazol** oral **contraceptive** fertility monkey

IT Fertility
(after discontinuation of **Danazol** as oral **contraceptive**, in monkey)

IT Macaca mulatta
(fertility after discontinuation of **Danazol** as oral **contraceptive** in)

IT 17230-88-5
RL: BIOL (Biological study)
(as oral **contraceptive**, fertility after discontinuation of, in monkey)

L10 ANSWER 20 OF 38 CA COPYRIGHT 2001 ACS

AN 104:200416 CA

TI The biochemistry of human endometrium after two regimens of postcoital contraception: a dl-norgestrel/ethinylestradiol combination or **danazol**

AU Kubba, Ali A.; White, John O.; Guillebaud, John; Elder, Murdoch G.

CS Margaret Pyke Cent., Hammersmith Hosp., London, W1V 5TW, UK

SO Fertil. Steril. (1986), 45(4), 512-16
CODEN: FESTAS; ISSN: 0015-0282

DT Journal

LA English

CC 2-3 (Mammalian Hormones)

AB A levonorgestrel-ethinylestradiol mixt. [39366-37-5] (0.5 and 0.1 mg, resp.) was administered to 8 volunteers 48 h after the start of the LH surge. A 2nd dose was given 12 h later. Endometrial samples were obtained 24 h after the 1st dose was given. The steroid receptor concn. was compared with ovulatory spontaneous cycles. The norgestrel-ethinylestradiol combination caused a redn. in receptor concn. Isocitrate dehydrogenase [9028-48-2] (a progestin-sensitive enzyme) was also altered, suggesting an effect on endometrial metab. **Danazol** [17230-88-5] was used in a similar fashion, with 2 doses each of 400 mg. A similar pattern of alteration of endometrial biochem. was demonstrated, but it did not reach significance. The relevance to the postcoital use of hormones is discussed.

ST uterus endometrium postcoital **contraceptive**; steroid receptor endometrium contraception

IT Receptors
RL: BIOL (Biological study)
(for estrogen and progesterone, of endometria, **contraceptives** effect on, in women)

IT Estrogens
RL: BIOL (Biological study)
(receptors for, of endometria, **contraceptives** effect on, in women)

IT Uterus, composition
(endometrium, isocitrate dehydrogenase and steroid receptors of human, after steroid **contraceptive** administration)

IT **Contraceptives**
(postcoital, isocitrate dehydrogenase and steroid receptors of endometria of women after treatment with)

IT 17230-88-5 39366-37-5
RL: BIOL (Biological study)
(isocitrate dehydrogenase and steroid receptors of endometria of women after treatment with)
IT 9028-48-2
RL: BIOL (Biological study)
(of endometrium, **contraceptives** effect on, in women)
IT 57-83-0, biological studies
RL: BIOL (Biological study)
(receptors for, of endometrium, **contraceptives** effect on, in women)

L10 ANSWER 19 OF 38 CA COPYRIGHT 2001 ACS
AN 105:165225 CA
TI A possible mechanism of action of **danazol** and an ethinylestradiol/norgestrel combination used as postcoital **contraceptive** agents
AU Rowlands, Sam; Kubba, Ali A.; Guillebaud, John; Bounds, Walli
CS Margaret Pyke Cent., London, W1V 5TW, UK
SO Contraception (1986), 33(6), 539-45
CODEN: CCPTAY; ISSN: 0010-7824
DT Journal
LA English
CC 2-3 (Mammalian Hormones)
AB Women requesting postcoital contraception were randomly allocated to take an ethinylestradiol-dl-norgestrel mixt. [8056-51-7] or **danazol** [17230-88-5]. Urine specimens were assayed for LH [9002-67-9] and pregnanediol-3-glucuronide [1852-49-9] levels from the day of the postcoital treatment to the next period. In addn., the urine samples of these recruits and addnl. women were assayed for the .beta.-subunit of human chorionic gonadotropin [9002-61-3]. A consistent pattern of alteration in urinary steroids was lacking, indicating a heterogenous effect on ovarian function. There was no evidence of early pregnancy in successfully treated cases. Evidently, the main mechanism of action of these drugs is at the endometrial level.
ST **contraceptive** postcoital endometrium; **danazol** postcoital **contraceptive**; ethynylestradiol norgestrel postcoital **contraceptive**
IT Corpus luteum
(function of, in ethynylestradiol-norgestrel mixt.- and **danazol** -induced postcoital contraception in women)
IT Urine
(gonadotropins and pregnanediol glucuronide of, ethynylestradiol-norgestrel mixt. and **danazol** effect on, in women, postcoital contraception in relation to)
IT Endocrine system
(anterior pituitary-hypothalamus, LH secretion regulation in, ethynylestradiol-norgestrel mixt. and **danazol** effect on, in postcoital contraception in women)
IT Uterus
(endometrium, ethynylestradiol-norgestrel mixt. and **danazol** effect on, in postcoital contraception in women)
IT **Contraceptives**
(postcoital, ethynylestradiol-norgestrel mixt. as, in women, mechanism for)
IT 8056-51-7 17230-88-5
RL: BIOL (Biological study)
(as postcoital **contraceptive**, in women, mechanism for)
IT 1852-49-9 9002-67-9
RL: BIOL (Biological study)
(of urine, of women, ethynylestradiol-norgestrel mixt. and **danazol** effect on, postcoital contraception in relation to)
IT 9002-61-3

RL: BIOL (Biological study)
(.beta.-subunit, of urine of human, ethynylestradiol-norgestrel mixt. and **danazol** effect on, postcoital contraception in relation to)

L10 ANSWER 6 OF 38 CA COPYRIGHT 2001 ACS
AN 127:341888 CA
TI Gestagens, **danazol** and antiprogestogen in emergency contraception
AU Webb, A. M. C.
CS North Mersey Community (NHS) Trust, Liverpool, L2 1TA, UK
SO Eur. J. Contracept. Reprod. Health Care (1997), 2(2), 127-129
CODEN: ECRCFK; ISSN: 1362-5187
PB Parthenon Publishing
DT Journal; General Review
LA English
CC 2-0 (Mammalian Hormones)
AB A review, with 9 refs. This paper describes work using progestogen alone , **danazol**, and the antiprogestogen mifepristone for emergency contraception.
ST review gestagen **danazol** antiprogestogen emergency contraception
IT Abortifacients
Contraceptives
(gestagens, **danazol** and antiprogestogen in emergency contraception)
IT Antiprogestins
Progestins
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gestagens, **danazol** and antiprogestogen in emergency contraception)
IT 17230-88-5, **Danazol** 84371-65-3, Mifepristone
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gestagens, **danazol** and antiprogestogen in emergency contraception)

L10 ANSWER 5 OF 38 CA COPYRIGHT 2001 ACS
AN 128:212540 CA
TI Application of emergency **contraceptives**
AU Tong, Jiansun; Cai, Reifeng
CS Jiangsu Family Planning Institute, Nanjing, 210029, Peop. Rep. China
SO Jiangsu Yiyao (1997), 23(11), 821
CODEN: CIYADX; ISSN: 0253-3685
PB Jiangsu Yiyao Bianjibu
DT Journal; General Review
LA Chinese
CC 1-0 (Pharmacology)
Section cross-reference(s): 2
AB A review with no refs. on the titled subject covering the use of estrogens, combined estrogen and progesterone, the progesterone like **danazol**, the antiprogesterone mifestone, anorethidrane dipropionate and centchroman, and problems and prospects.
ST review emergency **contraceptives**
IT **Contraceptives**
(application of emergency **contraceptives**)

=> D
L10 37 35 33 31 29 ALL

L10 ANSWER 37 OF 38 CA COPYRIGHT 2001 ACS

AN 81:58610 CA
TI Oral **contraceptive** activity of **danazol** in the rhesus monkey
AU Schane, H. Philip; Potts, Gordon O.
CS Sect. Endocrinol., Sterling-Winthrop Res. Inst., Rensselaer, N. Y., USA
SO Fert. Steril. (1974), 25(4), 363-6
CODEN: FESTAS
DT Journal
LA English
CC 2-5 (Hormone Pharmacology)
AB **Danazol** (I) [17230-88-5] was an effective oral **contraceptive** in the rhesus monkey. At a daily oral dose of 200 mg or 400 mg/monkey, no pregnancy occured during a 90 day treatment period.
ST **danazol contraceptive** monkey
IT Macaca mulatta
(**danazol** as **contraceptive** in)
IT **Contraceptives**
(**danazol** as, in monkey)
IT 17230-88-5
RL: BIOL (Biological study)
(as **contraceptive**, in monkey)

L10 ANSWER 35 OF 38 CA COPYRIGHT 2001 ACS
AN 85:719 CA
TI Investigation of **Danazol** as a **contraceptive** agent
AU Wentz, Anne C.; Jones, Georgeanna Seegar; Sapp, Karan C.
CS Dep. Gynecol. Obstet., Johns Hopkins Hosp., Baltimore, Md., USA
SO Contraception (1976), 13(5), 619-30
CODEN: CCPTAY
DT Journal
LA English
CC 2-6 (Hormone Pharmacology)
GI



I

AB **Danazol** (I) [17230-88-5] (400-1600 mg/day for the 1st 7 days of the menstrual cycle) lengthened the follicular phase and generally decreased serum FSH [9002-68-0] in women. The LH [9002-67-9] surge was normal, but delayed, and progesterone [57-83-0] output was normal during the luteal phase. Thus, an inadequate luteal phase was not induced by inhibition of FSH-stimulated follicular development.
ST **Danazol** ovarian cycle FSH LH; **contraceptive** **Danazol**
IT **Contraceptives**
(**Danazol**)
IT Ovarian cycle
(FSH and LH secretion in, **Danazol** effect on)
IT 17230-88-5
RL: BIOL (Biological study)
(FSH and LH secretion response to, in ovarian cycle)
IT 57-83-0, biological studies 9002-67-9 9002-68-0

RL: BIOL (Biological study)
(secretion of, in ovarian cycle, **Danazol** effect on)

L10 ANSWER 33 OF 38 CA COPYRIGHT 2001 ACS
AN 85:154410 CA
TI **Contraceptive** properties of **Danazol**
AU Colle, Michel L.; Greenblatt, Robert B.
CS Dep. Endocrinol., Med. Coll. Georgia, Augusta, Ga., USA
SO J. Reprod. Med. (1976), 17(2), 98-102
CODEN: JRPMAP
DT Journal
LA English
CC 2-6 (Hormone Pharmacology)
GI



I

AB Of 28 patients administered **Danazol** (I) [17230-88-5] (50 to 200 mg/day) for 90 days, none conceived while using the drug. I (200 mg/day) was the lowest dosage which consistently inhibited ovulation. Hypothalamic pituitary-ovarian imbalance did not follow these courses of therapy, as is sometimes obsd. after oral **contraceptives**. Regular ovulatory menses returned rapidly, and 3 patients conceived within 3 to 4 months after discontinuation of the drug. Side effects were minor. Apparently, I may be a useful **contraceptive** agent in women.
ST **Danazol contraceptive**
IT **Contraceptives**
(**Danazol** as, efficacy of)
IT Ovulation
(**Danazol** inhibition of, dose in relation to)
IT Blood serum
(gonadotropins of, **Danazol** effect on, ovulation in relation to)
IT Endocrine system
(hypothalamus-ovary-pituitary, **Danazol** effect on)
IT 17230-88-5
RL: BIOL (Biological study)
(**contraceptive** efficacy of)
IT 9002-67-9 9002-68-0
RL: BIOL (Biological study)
(of blood serum, **Danazol** effect on, contraception in relation to)

L10 ANSWER 31 OF 38 CA COPYRIGHT 2001 ACS
AN 87:48420 CA
TI Evaluation of **danazol** as an oral **contraceptive**
AU Lauersen, Niels H.; Wilson, Kathleen H.
CS New York Hosp., Cornell Univ. Med. Cent., New York, N. Y., USA
SO Obstet. Gynecol. (Hagerstown, Md.) (1977), 50(1), 91-6
CODEN: OBGNAS
DT Journal

LA English
CC 2-6 (Hormone Pharmacology)
GI



I

AB The effect of **danazol** (I) [17230-88-5] as an oral **contraceptive** in doses of 50, 100, and 200 mg daily for 6 months was studied in 3 groups of 10 women. Both 50 and 100 mg I daily were well tolerated but 1 pregnancy occurred among the women receiving 50 mg daily, and 2 pregnancies occurred in women receiving 100 mg daily. There were no pregnancies in women taking 200 mg I daily; however, the side effects were frequent and 5 of the 10 patients withdrew from the study prior to 6 months of therapy. Six patients in this study were followed intensively by blood hormone anal., vaginal cytol., and pathol. evaluation, and these findings are detailed.
ST **danazol** oral **contraceptive**
IT **Contraceptives**
(oral, **danazol** as, evaluation of)
IT 17230-88-5
RL: PROC (Process)
(as **contraceptive**, evaluation of)

L10 ANSWER 29 OF 38 CA COPYRIGHT 2001 ACS
AN 88:99610 CA
TI **Danazol** as a luteolytic agent
AU Wentz, Ann Colston; Sapp, Karan C.
CS Dep. Gynecol. Obstet., Johns Hopkins Univ. Sch. Med., Baltimore, Md., USA
SO Fertil. Steril. (1978), 29(1), 23-5
CODEN: FESTAS; ISSN: 0015-0282
DT Journal
LA English
CC 2-6 (Hormone Pharmacology)
GI



I

AB **Danazol** (I) [17230-88-5] was administered to healthy

nonpregnant volunteers to det. whether a luteolytic effect could be detected by observation of cycle length, duration of the luteal rise, and luteal steroidogenesis. I resulted in a decreased duration of the luteal rise and decreased progesterone [57-83-0] output in 3 of 4 subjects, but did not decrease total cycle length. The administration of human chorionic gonadotropin during I administration increased progesterone output. Therefore, I would apparently be ineffective as a leuteolytic **contraceptive** agent.

ST **danazol** corpus luteum lysis; luteolysis **danazol**

IT Corpus luteum
(lysis of, **danazol** effect on)

IT Blood plasma
(progesterone of, **danazol** effect on)

IT 17230-88-5
RL: BIOL (Biological study)
(corpus luteum lysis response to)

IT 57-83-0, properties
RL: FORM (Formation, nonpreparative)
(formation of, **danazol** effect on)

=> S L5 and l9

L11 103 L5 AND L9

=> s l9 and l5

L12 103 L9 AND L5

=> s l12 and l8

L13 1 L12 AND L8

=> d l13 all

L13 ANSWER 1 OF 1 CA COPYRIGHT 2001 ACS

AN 123:189355 CA

TI Ovulation control by regulating nitric oxide levels

IN Garfield, Robert E.; Yallampalli, Chandrasekhar

PA Board of Regents, University of Texas System, USA

SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-195

CC 2-3 (Mammalian Hormones)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9515753	A1	19950615	WO 1994-US14133	19941208
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5470847	A	19951128	US 1993-165309	19931210
	AU 9513041	A1	19950627	AU 1995-13041	19941208
	US 5643944	A	19970701	US 1995-477189	19950607
	US 5721278	A	19980224	US 1995-477187	19950607
PRAI	US 1993-165309		19931210		
	WO 1994-US14133		19941208		

AB Inhibition of ovulation in a female may be achieved by administering a nitric oxide synthase inhibitor, alone or in combination with one or more of a progestin, an estrogen, and an LH-RH antagonist, thereby preventing conception. The stimulation of ovulation in a female may be achieved by administering a nitric oxide source, optionally in further combination with one or more of clomiphene, a gonadotropin, and an LH-RH agonist. Thus, 27 days old immature rats were injected with 4 IU of pregnant mare's serum gonadotropin on day on. Two days later rats were injected with 40 mg of NG-nitro-L-arginine Me ester at 12 AM and 3 PM and animals were sacrificed one day later and examd. for the ovulatory response by counting the no. of Graafian follicles 3 and corpora lutea 5 in the ovaries. The no. of Graffian follicles and corpora lutea was 9.7 and 0.7 resp. as compared to 1.0 and 10.0 for the controls.

ST ovulation control nitric oxide synthase inhibition; conception prevention nitric oxide synthase inhibition

IT **Contraceptives**
Insemination, artificial
Ovarian cycle
Ovulation
Pituitary gland
(ovulation control by regulating nitric oxide levels)

IT Estrogens
Gonadotropins
Progestogens
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(ovulation control by regulating nitric oxide levels)

IT Fertilization
(extracorporeal, ovulation control by regulating nitric oxide levels)

IT Gonadotropins
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(inhibitors, ovulation control by regulating nitric oxide levels)

IT 9034-40-6, GnRH 103733-02-4
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(antagonists; ovulation control by regulating nitric oxide levels)

IT 50-28-2, 17.beta.-Estradiol, biological studies 50-50-0, Estradiol benzoate 55-63-0, Nitroglycerin 57-63-6, Ethinyl estradiol 57-83-0, Progesterone, biological studies 68-23-5, Norethinodrel 74-79-3, L-Arginine, biological studies 87-33-2, Isosorbide dinitrate 434-22-0, 19-Nortestosterone 520-85-4, Medroxyprogesterone 911-45-5, Clomiphene 2149-70-4 6533-00-2, Norgestrel 9002-67-9, LH 9034-40-6D, Lh-rh, analogs 14402-89-2, Sodium nitroprusside 16051-77-7, Isosorbide mononitrate 17035-90-4 17230-88-5, **Danazol** 20933-81-7 34973-08-5, Gonadorelin acetate 35189-28-7, **Norgestimate** 50903-99-6 54024-22-5, Desogestrel 57444-72-1 60282-87-3, Gestodene 74381-53-6, Leuprolide acetate 76932-60-0, Nafarelin acetate 125978-95-2, Nitric oxide synthase 137361-05-8
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(ovulation control by regulating nitric oxide levels)

=> d his

(FILE 'HOME' ENTERED AT 13:29:52 ON 14 MAY 2001)

FILE 'REGISTRY' ENTERED AT 13:29:59 ON 14 MAY 2001

```
                E CLOMIPHENE
L1            9 S E3
                E THIANAPHTHENE
L2          132 S E3

     FILE 'CA' ENTERED AT 13:31:10 ON 14 MAY 2001
L3         1272 S L1
L4         3002 S L2
                E CONTRACEPTIVE
L5        12649 S E3-E5
L6           34 S L3 AND L5
L7            8 S L4 AND L5
                E DANAZOL
L8          546 S E3
                E NORGESTERL
L9          167 S E1-E6
L10          38 S L8 AND L5
L11         103 S L5 AND L9
L12         103 S L9 AND L5
L13           1 S  L12 AND L8

=> s l11 and l3

L14           1 L11 AND L3

=> s l14 not l13

L15           0 L14 NOT L13

=> s l11 80-103

MISSING OPERATOR L11 80-103
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> d l11 80-103


L11  ANSWER 80 OF 103  CA  COPYRIGHT 2001 ACS
AN   115:198595  CA
TI   Characteristics of the new progestogens in combination oral
     contraceptives
AU   Rebar, R. W.; Zeserson, K.
CS   Med. Cent., Univ. Cincinnati, Cincinnati, OH, 45267-0526, USA
SO   Contraception (1991), 44(1), 1-10
     CODEN: CCPTAY; ISSN: 0010-7824
DT   Journal; General Review
LA   English

L11  ANSWER 81 OF 103  CA  COPYRIGHT 2001 ACS
AN   115:42163  CA
TI   Metabolism of norgestimate by human gastrointestinal mucosa and
     liver microsomes in vitro
AU   Madden, Stephen; Back, David J.
CS   Dep. Pharmacol. Therapeut., Univ. Liverpool, Liverpool, L69 3BX, UK
SO   J. Steroid Biochem. Mol. Biol. (1991), 38(4), 497-503
     CODEN: JSBBEZ
DT   Journal
LA   English

L11  ANSWER 82 OF 103  CA  COPYRIGHT 2001 ACS
AN   115:22416  CA
TI   Binding of oral contraceptive progestogens to serum proteins and
```

cytoplasmic receptors
AU Juchem, Michael; Pollow, Kunhard
CS Dep. Exp. Endocrinol., Johannes Gutenberg Univ., Mainz, 6500/1, Fed. Rep. Ger.
SO Am. J. Obstet. Gynecol. (1990), 163(6, Pt. 2), 2171-83
CODEN: AJOGAH; ISSN: 0002-9378
DT Journal
LA English

L11 ANSWER 83 OF 103 CA COPYRIGHT 2001 ACS
AN 114:240681 CA
TI Gastrointestinal metabolism of **contraceptive** steroids
AU Back, David J.; Madden, Steven; Orme, Michael L.
CS Dep. Pharmacol. Ther., Univ. Liverpool, Liverpool, L69 3BX, UK
SO Am. J. Obstet. Gynecol. (1990), 163(6, Pt. 2), 2138-45
CODEN: AJOGAH; ISSN: 0002-9378
DT Journal; General Review
LA English

L11 ANSWER 84 OF 103 CA COPYRIGHT 2001 ACS
AN 114:157323 CA
TI Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel,
norethisterone and **norgestimate** on the oxidation of ethinylestradiol and other substrates by human liver microsomes
AU Back, D. J.; Houlgrave, R.; Tjia, J. F.; Ward, S.; Orme, M. L.
CS Dep. Pharmacol. Ther., Univ. Liverpool, Liverpool, L69 3BX, UK
SO J. Steroid Biochem. Mol. Biol. (1991), 38(2), 219-25
CODEN: JSBBEZ
DT Journal
LA English

L11 ANSWER 85 OF 103 CA COPYRIGHT 2001 ACS
AN 113:91542 CA
TI Intermittent GnRH antagonist plus progestin contraception conserving tonic
ovarian estrogen secretion and reducing progestin exposure
AU Danforth, Douglas R.; Williams, Robert F.; Hsiu, Jeng G.; Roh, Sung I.; Hahn, DoWon; McGuire, John L.; Hodgen, Gary D.
CS Jones Inst. Reprod. Med., East. Virginia Med. Sch., Norfolk, VA, 23510, USA
SO Contraception (1990), 41(6), 623-31
CODEN: CCPTAY; ISSN: 0010-7824
DT Journal
LA English

L11 ANSWER 86 OF 103 CA COPYRIGHT 2001 ACS
AN 113:17978 CA
TI Progestational and androgenic receptor binding affinities and in vivo activities of **norgestimate** and other progestins
AU Phillips, A.; Demarest, K.; Hahn, D. W.; Wong, F.; McGuire, J. L.
CS R. W. Johnson Pharm. Res. Inst., Ortho Pharm. Corp., Raritan, NJ, 08869, USA
SO Contraception (1990), 41(4), 399-410
CODEN: CCPTAY; ISSN: 0010-7824
DT Journal
LA English

L11 ANSWER 87 OF 103 CA COPYRIGHT 2001 ACS
AN 112:133193 CA
TI Estrogen-progestin combinations as **contraceptives**
IN Casper, Robert F.
PA Jencap Research Ltd., Can.

SO Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 309263	A2	19890329	EP 1988-308840	19880923
	EP 309263	A3	19890802		
	EP 309263	B1	19940309		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	CA 1332227	A1	19941004	CA 1987-547743	19870924
	CA 1332228	A1	19941004	CA 1987-547744	19870924
	FI 8804378	A	19890325	FI 1988-4378	19880923
	NO 8804230	A	19890328	NO 1988-4230	19880923
	AU 8822760	A1	19890406	AU 1988-22760	19880923
	AU 630334	B2	19921029		
	DK 8805296	A	19890525	DK 1988-5296	19880923
	ZA 8807127	A	19890628	ZA 1988-7127	19880923
	HU 50043	A2	19891228	HU 1988-4989	19880923
	HU 214598	B	19980428		
	EP 559240	A2	19930908	EP 1993-107794	19880923
	EP 559240	A3	19931222		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 102484	E	19940315	AT 1988-308840	19880923
	ES 2061672	T3	19941216	ES 1988-308840	19880923
	JP 01132523	A2	19890525	JP 1988-239566	19880924
	CN 1041528	A	19900425	CN 1988-107593	19880924
	CN 1042296	B	19990303		
	JP 11286446	A2	19991019	JP 1998-344823	19880924
	AU 9230448	A1	19930211	AU 1992-30448	19921224
	FI 9702370	A	19970604	FI 1997-2370	19970604
PRAI	CA 1987-547743		19870924		
	CA 1987-547744		19870924		
	EP 1988-308840		19880923		
	FI 1988-4378		19880923		
	JP 1988-239566		19880924		

L11 ANSWER 88 OF 103 CA COPYRIGHT 2001 ACS
AN 111:17789 CA
TI Clinical aspects of three new progestogens: desogestrel, gestodene, and **norgestimate**
AU Chez, Ronald A.
CS New Jersey Med. Sch., Univ. Med. Dent. New Jersey, Newark, NJ, USA
SO Am. J. Obstet. Gynecol. (1989), 160(5, Pt. 2), 1296-300
CODEN: AJOGAH; ISSN: 0002-9378
DT Journal; General Review
LA English

L11 ANSWER 89 OF 103 CA COPYRIGHT 2001 ACS
AN 110:128753 CA
TI A study on the effect of short acting norgestrel compound on sister chromatid exchange (SCE) frequency
AU Han, Tielan; Wang, Huirong; Liu, Guirong; Ma, Zhujia; Hua, Huipei; Li, Yuxin; Qiao, Huizhen
CS Dep. Obstert. Gynecol., Inner Mongolia Med. Coll., Hohhot, Peop. Rep. China
SO Shengzhi Yu Biyun (1988), 8(2), 58-9
CODEN: SCYYDZ; ISSN: 0253-357X
DT Journal
LA Chinese

L11 ANSWER 90 OF 103 CA COPYRIGHT 2001 ACS

AN 110:108362 CA
TI Effect of compound quinestrol on lipid metabolism
AU Zhu, Xixing; Chen, Hongji; Qian, Hongkan; Qiu, Chuanlu; Lu, Xiangyun; Yan,
Benyuan
CS Diabetes Res. Dep., Hua Shan Hosp., Shanghai, Peop. Rep. China
SO Shengzhi Yu Biyun (1988), 8(2), 19-21, 41
CODEN: SCYYDZ; ISSN: 0253-357X
DT Journal
LA Chinese

L11 ANSWER 91 OF 103 CA COPYRIGHT 2001 ACS
AN 109:183599 CA
TI New progestogens
AU Koehler, G.; Goeretzlehner, G.
CS Klin. Poliklin. Gynaekol. Geburtshilfe, Ernst-Moritz-Arndt Univ., Greifswald, Ger. Dem. Rep.
SO Zentralbl. Gynaekol. (1988), 110(13), 801-8
CODEN: ZEGYAX; ISSN: 0044-4197
DT Journal; General Review
LA German

L11 ANSWER 92 OF 103 CA COPYRIGHT 2001 ACS
AN 108:88200 CA
TI New progestogens in oral **contraceptives**
AU Runnebaum, Benno; Rabe, Thomas
CS Dep. Obstet. Cynecol., Univ. Heidelberg, Heidelberg, Fed. Rep. Ger.
SO Am. J. Obstet. Gynecol. (1987), 157(4, Pt. 2), 1059-63
CODEN: AJOGAH; ISSN: 0002-9378
DT Journal
LA English

L11 ANSWER 93 OF 103 CA COPYRIGHT 2001 ACS
AN 108:88175 CA
TI **Contraceptive** progestins and gonadotropin secretion in vitro
AU Kiesel, Ludwig; Helm, Klauss; Bertges, Karin; Maier, Christiane; Rabe, Thomas; Runnebaum, Benno
CS Div. Gynecol. Endocrinol., Univ. Heidelberg, Heidelberg, D-6900, Fed. Rep.
Ger.
SO J. Steroid Biochem. (1987), 27(4-6), 995-1002
CODEN: JSTBBK; ISSN: 0022-4731
DT Journal
LA English

L11 ANSWER 94 OF 103 CA COPYRIGHT 2001 ACS
AN 108:69143 CA
TI Comparative study of the pharmacological properties of levonorgestrel and **norgestimate**
AU Cao, Lumin; Du, Qingling; Li, Wan; Wu, Xirui
CS Family Plann. Res. Inst., Tongji Med. Univ., Wuhan, Peop. Rep. China
SO Tongji Yike Daxue Xuebao (1987), 16(5), 326-9
CODEN: TYDXEP
DT Journal
LA Chinese

L11 ANSWER 95 OF 103 CA COPYRIGHT 2001 ACS
AN 108:734 CA
TI A comparison of the potencies and activities of progestogens used in **contraceptives**
AU Phillips, Audrey; Hahn, Do Won; Klimek, Susan; McGuire, John L.
CS Res. Lab., Ortho Pharm. Corp., Raritan, NJ, 08869, USA
SO Contraception (1987), 36(2), 181-92

CODEN: CCPTAY; ISSN: 0010-7824
DT Journal
LA English

L11 ANSWER 96 OF 103 CA COPYRIGHT 2001 ACS
AN 105:108726 CA
TI Effects of **norgestimate** (0.250 mg) in combination with ethinyl estradiol (0.035 mg) on cervical mucus
AU Hull, M. E.; Moghissi, K. S.
CS Sch. Med., Wayne State Univ., Detroit, MI, 48201, USA
SO Adv. Contracept. (1986), 2(1), 71-7
CODEN: ADCOEB
DT Journal
LA English

L11 ANSWER 97 OF 103 CA COPYRIGHT 2001 ACS
AN 102:154742 CA
TI Biodegradable and nonbiodegradable fibrous delivery systems
AU Cowsar, Donald R.; Dunn, Richard L.
CS Southern Res. Inst., Birmingham, AL, USA
SO Long-Acting Contracept. Delivery Syst., [Proc. Int. Workshop] (1984), Meeting Date 1983, 145-63. Editor(s): Zatuchni, Gerald I. Publisher: Harper & Row, Philadelphia, Pa.
CODEN: 53DIAN
DT Conference
LA English

L11 ANSWER 98 OF 103 CA COPYRIGHT 2001 ACS
AN 102:154741 CA
TI Development of microencapsulated **norgestimate** as a long-acting **contraceptive**
AU Hahn, Do Won; McGuire, John L.; Cohn, Robert M.; Beck, Lee R.; Tice, Thomas R.; Lewis, Danny H.
CS Ortho Pharm. Corp., Raritan, NJ, USA
SO Long-Acting Contracept. Delivery Syst., [Proc. Int. Workshop] (1984), Meeting Date 1983, 96-112. Editor(s): Zatuchni, Gerald I. Publisher: Harper & Row, Philadelphia, Pa.
CODEN: 53DIAN
DT Conference
LA English

L11 ANSWER 99 OF 103 CA COPYRIGHT 2001 ACS
AN 102:137733 CA
TI Polymeric considerations in the design of microencapsulation of **contraceptive** steroids
AU Lewis, Danny H.; Tice, Thomas R.
CS Stable Res. Dev. Corp., Birmingham, AL, USA
SO Long-Acting Contracept. Delivery Syst., [Proc. Int. Workshop] (1984), Meeting Date 1983, 77-95. Editor(s): Zatuchni, Gerald I. Publisher: Harper & Row, Philadelphia, Pa.
CODEN: 53DIAN
DT Conference
LA English

L11 ANSWER 100 OF 103 CA COPYRIGHT 2001 ACS
AN 95:215629 CA
TI Effects of **norgestimate** in combination with ethinyl estradiol on cervical mucus
AU Mohsenian, Mohammad; Moghissi, Kamran S.; Borin, Katherine
CS Sch. Med., Wayne State Univ., Detroit, MI, 48201, USA
SO Contraception (1981), 24(2), 173-81
CODEN: CCPTAY; ISSN: 0010-7824
DT Journal

LA English

L11 ANSWER 101 OF 103 CA COPYRIGHT 2001 ACS
AN 95:18826 CA
TI Clinical performance and endocrine profiles with **contraceptive** vaginal rings containing a combination of estradiol and D-norgestrel
AU Mehta, S.; Joshi, U. M.; Sankolli, G. M.; Adatia, A.; Donde, U. M.; Saxena, B. N.
CS Inst. Res. Reprod., Bombay, 400 012, India
SO Contraception (1981), 23(3), 241-50
CODEN: CCPTAY; ISSN: 0010-7824
DT Journal
LA English

L11 ANSWER 102 OF 103 CA COPYRIGHT 2001 ACS
AN 92:34702 CA
TI Pharmacokinetics of levonorgestrel in Indian women belonging to low socio-economic group
AU Nair, K. Madhavan; Sivakumar, B.; Prema, K.; Rao, B. S. Narasinga
CS Natl. Inst. Nutr., Indian Counc. Med. Res., Hyderabad, 500 007, India
SO Contraception (1979), 20(3), 303-17
CODEN: CCPTAY; ISSN: 0010-7824
DT Journal
LA English

L11 ANSWER 103 OF 103 CA COPYRIGHT 2001 ACS
AN 67:18204 CA
TI Interactions of ethynyl estradiol and **norgesterel** (dl-13.beta.-ethyl-17.alpha.-ethynyl-17.beta.-hydroxygon-4-en-3-one; WY 3707)
AU Edgren, Richard A.; Jones, Robert Clyde; Clancy, DeAnn P.; Gillen, Anne L.
CS Res. Div., Wyeth Labs., Philadelphia, Pa., USA
SO Acta Endocrinol. (Copenhagen), Suppl. (1967), No. 115, 21 pp.
CODEN: ACEDAB
DT Journal
LA English

=> d l11 98 94 88 87 all

L11 ANSWER 98 OF 103 CA COPYRIGHT 2001 ACS
AN 102:154741 CA
TI Development of microencapsulated **norgestimate** as a long-acting **contraceptive**
AU Hahn, Do Won; McGuire, John L.; Cohn, Robert M.; Beck, Lee R.; Tice, Thomas R.; Lewis, Danny H.
CS Ortho Pharm. Corp., Raritan, NJ, USA
SO Long-Acting Contracept. Delivery Syst., [Proc. Int. Workshop] (1984), Meeting Date 1983, 96-112. Editor(s): Zatuchni, Gerald I. Publisher: Harper & Row, Philadelphia, Pa.
CODEN: 53DIAN
DT Conference
LA English
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 2
GI



I

AB Biodegradable microcapsules contg. **norgestimate** (I) [35189-28-7] were prepd. by a solvent-evapn. method as a long-active **contraceptive** using poly-dl-lactide [26680-10-4] or poly(dl-lactide-co-glycolide) [26780-50-7] as the biodegradable polymer. Encapsulation efficiency was 81.8-91.2% of theory. In vitro rate of I dissoln. from microcapsules was detd. by a shaker-bath method, and the amt. released was detd. spectrophotometrically. Smaller microcapsules have a faster rate of drug release, and hence a shorter duration of action. Sterilization increased the rate of I release. Treatment of cycling rats with I in various sizes of microcapsules of either polymer showed that inhibition of estrus cyclicity was dependent on dose level, microcapsule size, and polymer compn. Treatment of baboons with various doses of microencapsulated I suppressed ovarian function .ltoreq.6 mo in a dose-related manner.

ST **norgestimate** microencapsulation long acting **contraceptive**; polylactide microencapsule **norgestimate** **contraceptive**; polyglycolide microcapsule **norgestimate** **contraceptive**; polyester microcapsule **norgestimate** **contraceptive**

IT Sterilization and Disinfection
(**norgestimate** **contraceptive** release from lactide-based polyester microcapsules in relation to)

IT **Contraceptives**
(**norgestimate**, encapsulation of, in polylactides, long-acting)

IT Solution rate
(of **norgestimate** **contraceptive**, from lactide-based polyesters)

IT Polyesters, biological studies
RL: BIOL (Biological study)
(glycolide-lactide, **norgestimate** long-acting **contraceptive** encapsulation in)

IT Polyesters, biological studies
RL: BIOL (Biological study)
(lactide, **norgestimate** long-acting **contraceptive** encapsulation in)

IT Encapsulation
(micro-, by polylactides, of **norgestimate** long-acting **contraceptive**)

IT Capsules, pharmaceutical
(micro-, lactide-based polyesters, prepn. of and **norgestimate** **contraceptive** release from)

IT 35189-28-7
RL: BIOL (Biological study)
(**contraceptive**, encapsulation of, in polylactides, long-acting)

IT 26680-10-4 26780-50-7 51063-13-9
RL: BIOL (Biological study)
(**norgestimate** long-acting **contraceptive** encapsulation in)

L11 ANSWER 94 OF 103 CA COPYRIGHT 2001 ACS
AN 108:69143 CA
TI Comparative study of the pharmacological properties of levonorgestrel and **norgestimate**
AU Cao, Lumin; Du, Qingling; Li, Wan; Wu, Xirui
CS Family Plann. Res. Inst., Tongji Med. Univ., Wuhan, Peop. Rep. China
SO Tongji Yike Daxue Xuebao (1987), 16(5), 326-9
CODEN: TYDXEP
DT Journal
LA Chinese
CC 2-3 (Mammalian Hormones)
AB The sex hormone actions and antiovulatory potency of native levonorgestrel and **norgestimate** were detd. in rats, mice, and rabbits. In the assay of progestagen activity, orally administered **norgestimate** and levonorgestrel were 2.4- and 2.2-fold, resp., more potent than s.c. administered progesterone. In tests of pregnancy maintenance in ovariectomized rats, **norgestimate** showed stronger activity than levonorgestrel. The uterotropic activity of both progestins in immature mice were very weak (orally administered **norgestimate** .apprx.8.0 .times. 10-8, levonorgestrel .apprx.18.6 .times. 10-6, as potent as s.c. administered ethinylestradiol). Neither **norgestimate** nor levonorgestrel caused vaginal cornification at 10 mg/kg in castrated mice.
Both progestins showed very weak androgenic activity (**norgestimate** weaker than levonorgestrel). The antiovulatory effect of **norgestimate** in rabbits was much stronger than that of levonorgestrel.
ST levonorgestrel **norgestimate contraceptive** progestogen
IT Ovulation
(inhibition of, by levonorgestrel and **norgestimate**)
IT Progestogens
RL: BIOL (Biological study)
(levonorgestrel and **norgestimate** as, oral **contraceptive** action in relation to)
IT **Contraceptives**
(oral, levonorgestrel and **norgestimate** as, progestogen and antiovulatory activities of)
IT 6533-00-2 35189-28-7, **Norgestimate**
RL: BIOL (Biological study)
(progestogen and antiovulatory activity of, oral **contraceptive** action in relation to)

L11 ANSWER 88 OF 103 CA COPYRIGHT 2001 ACS
AN 111:17789 CA
TI Clinical aspects of three new progestogens: desogestrel, gestodene, and **norgestimate**
AU Chez, Ronald A.
CS New Jersey Med. Sch., Univ. Med. Dent. New Jersey, Newark, NJ, USA
SO Am. J. Obstet. Gynecol. (1989), 160(5, Pt. 2), 1296-300
CODEN: AJOGAH; ISSN: 0002-9378
DT Journal; General Review
LA English
CC 2-0 (Mammalian Hormones)
AB A review, with 30 refs., of the clin. aspects of oral **contraceptives** contg. desogestrel, gestodene, or **norgestimate**. Clin. categories considered were: **contraceptive** efficacy, cycle control, side effects, and alterations in protein, carbohydrate, and lipid metab.
ST review progestogen oral **contraceptive**; desogestrel oral **contraceptive** review; gestodene oral **contraceptive** review; **norgestimate** oral **contraceptive** review
IT **Contraceptives**

(oral, desogestrel and gestodene and **norgestimate**, clin. aspects of, in human)
IT 35189-28-7, **Norgestimate** 54024-22-5, Desogestrel 60282-87-3
RL: BIOL (Biological study)
(oral **contraceptives** contg., clin. aspects of, in humans)

L11 ANSWER 87 OF 103 CA COPYRIGHT 2001 ACS
AN 112:133193 CA
TI Estrogen-progestin combinations as **contraceptives**
IN Casper, Robert F.
PA Jencap Research Ltd., Can.
SO Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM A61K031-565
CC 2-3 (Mammalian Hormones)
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 309263	A2	19890329	EP 1988-308840	19880923
	EP 309263	A3	19890802		
	EP 309263	B1	19940309		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	CA 1332227	A1	19941004	CA 1987-547743	19870924
	CA 1332228	A1	19941004	CA 1987-547744	19870924
	FI 8804378	A	19890325	FI 1988-4378	19880923
	NO 8804230	A	19890328	NO 1988-4230	19880923
	AU 8822760	A1	19890406	AU 1988-22760	19880923
	AU 630334	B2	19921029		
	DK 8805296	A	19890525	DK 1988-5296	19880923
	ZA 8807127	A	19890628	ZA 1988-7127	19880923
	HU 50043	A2	19891228	HU 1988-4989	19880923
	HU 214598	B	19980428		
	EP 559240	A2	19930908	EP 1993-107794	19880923
	EP 559240	A3	19931222		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 102484	E	19940315	AT 1988-308840	19880923
	ES 2061672	T3	19941216	ES 1988-308840	19880923
	JP 01132523	A2	19890525	JP 1988-239566	19880924
	CN 1041528	A	19900425	CN 1988-107593	19880924
	CN 1042296	B	19990303		
	JP 11286446	A2	19991019	JP 1998-344823	19880924
	AU 9230448	A1	19930211	AU 1992-30448	19921224
	FI 9702370	A	19970604	FI 1997-2370	19970604
PRAI	CA 1987-547743		19870924		
	CA 1987-547744		19870924		
	EP 1988-308840		19880923		
	FI 1988-4378		19880923		
	JP 1988-239566		19880924		

AB A combination of estrogen and progestin is used for contraception, where a
short period of relatively dominant estrogenic activity alternates with a short period of relatively dominant progestagenic activity. The combination is also used for hormone replacement therapy in menopausal or castrated women. A plurality of unit doses (preferably .apprxeq.3) of relatively dominant estrogenic activity is alternated with a similar plurality of unit doses of relatively dominant progestagenic activity, with each package contg. 20-35 unit doses. This combination provides improved cycle control. Intermittent increases in estrogen activity stimulate endometrial growth and progestin receptors. This makes the endometrium more sensitive to subsequent progestin administration, which limits growth by decreasing estrogen receptors and increasing

17.beta.-hydroxy steroid dehydrogenase. Interaction of progestin with progestin receptors induces secretory changes in the endometrium which results in a denser stroma and endometrial stability. A return to relatively dominant estrogenic activity then again stimulates estrogen and progestin receptors and renews endometrial sensitivity to progestin. This push-pull activity keeps endometrial activity within a narrow range depending on the no. of days of estrogenic and progestagenic activity. Thus, 3-day phases of unit dosages of 0.035 mg 17.alpha.-ethynylestradiol and 0.5 mg norethindrone were alternated with 3-day phases of unit dosages of 0.035 mg ethynylestradiol and 0.75 mg norethindrone, beginning and ending with the 0.75 mg norethindrone combination, for 7 phases (21 days), beginning on day 5 after the onset of menstruation. This regimen was followed by a 7-day hormone-free interval. The subject had no bleeding or spotting while taking the test formulation, and had a withdrawal bleed starting on the 2nd day of the hormone-free interval and lasting 5 days.

ST **contraceptive** estrogen progestagen combination

IT Progestogens
RL: BIOL (Biological study)
(-estrogen combinations, as **contraceptives** and for hormone replacement therapy)

IT Estrogens
RL: BIOL (Biological study)
(-progestagen combinations, as **contraceptives** and for hormone replacement therapy)

IT **Contraceptives**
(estrogen-progestagen combinations)

IT Menopause
Ovariectomy
(hormone replacement therapy in, with estrogen-progestagen combinations)

IT 50-27-1D, Estriol, mixts. with progestagens 50-28-2D, 17.beta.-Estradiol, mixts. with progestagens 51-98-9D, Norethindrone acetate, mixts. with estrogens 52-76-6D, mixts. with estrogens 53-16-7D, Estrone, mixts. with progestagens 53-16-7D, polyphosphates, mixts. with progestagens 57-63-6D, 17.alpha.-Ethinylestradiol, mixts. with progestagens 57-83-0D, Progesterone, mixts. with estrogens 68-22-4D, Norethindrone, mixts. with estrogens 68-23-5D, Norethynodrel, mixts. with estrogens 68-96-2D, esters, mixts. with estrogens 71-58-9D, Medroxyprogesterone acetate, mixts. with estrogens 72-33-3D, Mestranol, mixts. with progestagens 79-64-1D, Dimethisterone, mixts. with estrogens 152-62-5D, Dydrogesterone, mixts. with estrogens 297-76-7D, Ethynodiol diacetate, mixts. with estrogens 427-51-0D, Cyproterone acetate, mixts. with estrogens 432-60-0D, Allylestrenol, mixts. with estrogens 434-03-7D, Ethisterone, mixts. with estrogens 481-97-0D, Estrone sulphate, mixts. with progestagens 514-68-1D, Estriol succinate, mixts. with progestagens 797-63-7D, Levonorgestrel, mixts. with estrogens 797-64-8D, mixts. with estrogens 848-21-5D, mixts. with estrogens 977-79-7D, Medrogestone, mixts. with estrogens 979-32-8D, Estradiol valerate, mixts. with progestagens 1169-79-5D, mixts. with progestagens 2098-66-0D, Cyproterone, mixts. with estrogens 3000-39-3D, Quingestanol acetate, mixts. with estrogens 6533-00-2D, DL-Norgestrel, mixts. with estrogens 7280-37-7D, mixts. with progestagens 35189-28-7D, **Norgestimate**, mixts. with estrogens 37270-71-6 54024-22-5D, Desogestrel, mixts. with estrogens 60282-87-3D, Gestodene, mixts. with estrogens 62057-27-6 125670-28-2
RL: BIOL (Biological study)

(as **contraceptives** and for hormone replacement therapy)

```
=> d his

     (FILE 'HOME' ENTERED AT 13:29:52 ON 14 MAY 2001)

     FILE 'REGISTRY' ENTERED AT 13:29:59 ON 14 MAY 2001
                E CLOMIPHENE
L1            9 S E3
                E THIANAPHTHENE
L2          132 S E3

     FILE 'CA' ENTERED AT 13:31:10 ON 14 MAY 2001
L3         1272 S L1
L4         3002 S L2
                E CONTRACEPTIVE
L5        12649 S E3-E5
L6           34 S L3 AND L5
L7            8 S L4 AND L5
                E DANAZOL
L8          546 S E3
                E NORGESTERL
L9          167 S E1-E6
L10          38 S L8 AND L5
L11         103 S L5 AND L9
L12         103 S L9 AND L5
L13           1 S  L12 AND L8
L14           1 S L11 AND L3
L15           0 S L14 NOT L13

=>

---Logging off of STN---


=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               206.87     215.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                               -19.60     -19.60

STN INTERNATIONAL LOGOFF AT 14:12:03 ON 14 MAY 2001
```